id	sid	tid	token	lemma	pos
aji-173	1	1	_	_	PUNCT
aji-173	2	1	_	_	PUNCT
aji-173	3	1	_	_	PUNCT
aji-173	4	1	_	_	PUNCT
aji-173	5	1	_	_	PUNCT
aji-173	6	1	_	_	PUNCT
aji-173	7	1	_	_	PUNCT
aji-173	8	1	_	_	PUNCT
aji-173	9	1	_	_	PUNCT
aji-173	10	1	_	_	PUNCT
aji-173	11	1	_	_	PUNCT
aji-173	12	1	_	_	PUNCT
aji-173	13	1	_	_	PUNCT
aji-173	14	1	_	_	PUNCT
aji-173	15	1	_	_	PUNCT
aji-173	16	1	_	_	PUNCT
aji-173	17	1	_	_	PUNCT
aji-173	18	1	_	_	PUNCT
aji-173	19	1	_	_	PUNCT
aji-173	20	1	_	_	PUNCT
aji-173	21	1	_	_	PUNCT
aji-173	22	1	_	_	PUNCT
aji-173	23	1	_	_	PUNCT
aji-173	24	1	_	_	PUNCT
aji-173	25	1	_	_	PUNCT
aji-173	26	1	_	_	PUNCT
aji-173	27	1	_	_	PUNCT
aji-173	28	1	_	_	PUNCT
aji-173	29	1	_	_	PUNCT
aji-173	30	1	_	_	PUNCT
aji-173	31	1	_	_	PUNCT
aji-173	32	1	_	_	PUNCT
aji-173	33	1	_	_	PUNCT
aji-173	34	1	_	_	PUNCT
aji-173	35	1	_	_	PUNCT
aji-173	36	1	_	_	PUNCT
aji-173	37	1	_	_	PUNCT
aji-173	38	1	_	_	PUNCT
aji-173	39	1	_	_	PUNCT
aji-173	40	1	_	_	PUNCT
aji-173	41	1	_	_	PUNCT
aji-173	42	1	_	_	PUNCT
aji-173	43	1	_	_	PUNCT
aji-173	44	1	_	_	PUNCT
aji-173	45	1	_	_	PUNCT
aji-173	46	1	_	_	PUNCT
aji-173	47	1	_	_	PUNCT
aji-173	48	1	_	_	PUNCT
aji-173	49	1	_	_	PUNCT
aji-173	50	1	_	_	PUNCT
aji-173	51	1	_	_	PUNCT
aji-173	52	1	_	_	PUNCT
aji-173	53	1	_	_	PUNCT
aji-173	54	1	_	_	PUNCT
aji-173	55	1	_	_	PUNCT
aji-173	56	1	_	_	PUNCT
aji-173	57	1	_	_	PUNCT
aji-173	58	1	_	_	PUNCT
aji-173	59	1	_	_	PUNCT
aji-173	60	1	_	_	PUNCT
aji-173	61	1	_	_	PUNCT
aji-173	62	1	_	_	PUNCT
aji-173	63	1	_	_	PUNCT
aji-173	64	1	_	_	PUNCT
aji-173	65	1	_	_	PUNCT
aji-173	66	1	_	_	PUNCT
aji-173	67	1	_	_	PUNCT
aji-173	68	1	_	_	PUNCT
aji-173	69	1	_	_	PUNCT
aji-173	70	1	_	_	PUNCT
aji-173	71	1	_	_	PUNCT
aji-173	72	1	_	_	PUNCT
aji-173	73	1	_	_	PUNCT
aji-173	74	1	_	_	PUNCT
aji-173	75	1	_	_	PUNCT
aji-173	76	1	_	_	PUNCT
aji-173	77	1	_	_	PUNCT
aji-173	78	1	_	_	PUNCT
aji-173	79	1	_	_	PUNCT
aji-173	80	1	_	_	PUNCT
aji-173	81	1	_	_	PUNCT
aji-173	82	1	_	_	PUNCT
aji-173	83	1	_	_	PUNCT
aji-173	84	1	_	_	PUNCT
aji-173	85	1	_	_	PUNCT
aji-173	86	1	_	_	PUNCT
aji-173	87	1	_	_	PUNCT
aji-173	88	1	_	_	PUNCT
aji-173	89	1	_	_	PUNCT
aji-173	90	1	_	_	PUNCT
aji-173	91	1	_	_	PUNCT
aji-173	92	1	_	_	PUNCT
aji-173	93	1	_	_	PUNCT
aji-173	94	1	_	_	PUNCT
aji-173	95	1	_	_	PUNCT
aji-173	96	1	_	_	PUNCT
aji-173	97	1	_	_	PUNCT
aji-173	98	1	_	_	PUNCT
aji-173	99	1	_	_	PUNCT
aji-173	100	1	_	_	PUNCT
aji-173	101	1	_	_	PUNCT
aji-173	102	1	*	*	PUNCT
aji-173	102	2	corresponding	correspond	VERB
aji-173	102	3	author	author	NOUN
aji-173	102	4	:	:	PUNCT
aji-173	102	5	e	e	NOUN
aji-173	102	6	-	-	NOUN
aji-173	102	7	mail	mail	NOUN
aji-173	102	8	:	:	PUNCT
aji-173	102	9	meriche.h23@gmail.com	meriche.h23@gmail.com	X
aji-173	102	10	;	;	PUNCT
aji-173	102	11	cite	cite	VERB
aji-173	102	12	as	as	ADP
aji-173	102	13	:	:	PUNCT
aji-173	102	14	hacene	hacene	PROPN
aji-173	102	15	meriche	meriche	PROPN
aji-173	102	16	,	,	PUNCT
aji-173	102	17	sara	sara	PROPN
aji-173	102	18	zaghez	zaghez	PROPN
aji-173	102	19	,	,	PUNCT
aji-173	102	20	feriel	feriel	PROPN
aji-173	102	21	sandra	sandra	PROPN
aji-173	102	22	bouafia	bouafia	PROPN
aji-173	102	23	,	,	PUNCT
aji-173	102	24	boutheina	boutheina	PROPN
aji-173	102	25	abdaoui	abdaoui	PROPN
aji-173	102	26	,	,	PUNCT
aji-173	102	27	nacima	nacima	PROPN
aji-173	102	28	sabiha	sabiha	PROPN
aji-173	102	29	gadiri	gadiri	NOUN
aji-173	102	30	,	,	PUNCT
aji-173	102	31	and	and	CCONJ
aji-173	102	32	hichem	hichem	NOUN
aji-173	102	33	frigaa	frigaa	PROPN
aji-173	102	34	.	.	PUNCT
aji-173	103	1	2025	2025	NUM
aji-173	103	2	.	.	PUNCT
aji-173	104	1	“	"	PUNCT
aji-173	104	2	symptomatic	symptomatic	ADJ
aji-173	104	3	multiple	multiple	ADJ
aji-173	104	4	myeloma	myeloma	NOUN
aji-173	104	5	in	in	ADP
aji-173	104	6	the	the	DET
aji-173	104	7	second	second	ADJ
aji-173	104	8	trimester	trimester	NOUN
aji-173	104	9	of	of	ADP
aji-173	104	10	pregnancy	pregnancy	NOUN
aji-173	104	11	:	:	PUNCT
aji-173	104	12	a	a	DET
aji-173	104	13	case	case	NOUN
aji-173	104	14	report	report	NOUN
aji-173	104	15	”	"	PUNCT
aji-173	104	16	.	.	PUNCT
aji-173	105	1	asian	asian	ADJ
aji-173	105	2	journal	journal	NOUN
aji-173	105	3	of	of	ADP
aji-173	105	4	immunology	immunology	NOUN
aji-173	105	5	8	8	NUM
aji-173	105	6	(	(	PUNCT
aji-173	105	7	1):222–229	1):222–229	NUM
aji-173	105	8	.	.	PUNCT
aji-173	106	1	https://doi.org/10.9734/aji/2025/v8i1173	https://doi.org/10.9734/aji/2025/v8i1173	PROPN
aji-173	106	2	.	.	PUNCT
aji-173	107	1	asian	asian	PROPN
aji-173	107	2	journal	journal	PROPN
aji-173	107	3	of	of	ADP
aji-173	107	4	immunology	immunology	NOUN
aji-173	107	5	volume	volume	NOUN
aji-173	107	6	8	8	NUM
aji-173	107	7	,	,	PUNCT
aji-173	107	8	issue	issue	NOUN
aji-173	107	9	1	1	NUM
aji-173	107	10	,	,	PUNCT
aji-173	107	11	page	page	NOUN
aji-173	107	12	222	222	NUM
aji-173	107	13	-	-	SYM
aji-173	107	14	229	229	NUM
aji-173	107	15	,	,	PUNCT
aji-173	107	16	2025	2025	NUM
aji-173	107	17	;	;	PUNCT
aji-173	107	18	article	article	NOUN
aji-173	107	19	no.aji.141940	no.aji.141940	NOUN
aji-173	107	20	symptomatic	symptomatic	ADJ
aji-173	107	21	multiple	multiple	ADJ
aji-173	107	22	myeloma	myeloma	NOUN
aji-173	107	23	in	in	ADP
aji-173	107	24	the	the	DET
aji-173	107	25	second	second	ADJ
aji-173	107	26	trimester	trimester	NOUN
aji-173	107	27	of	of	ADP
aji-173	107	28	pregnancy	pregnancy	NOUN
aji-173	107	29	:	:	PUNCT
aji-173	107	30	a	a	DET
aji-173	107	31	case	case	NOUN
aji-173	107	32	report	report	NOUN
aji-173	107	33	hacene	hacene	NOUN
aji-173	107	34	meriche	meriche	PROPN
aji-173	107	35	a	a	PROPN
aji-173	107	36	*	*	PROPN
aji-173	107	37	,	,	PUNCT
aji-173	107	38	sara	sara	PROPN
aji-173	107	39	zaghez	zaghez	PROPN
aji-173	107	40	a	a	PROPN
aji-173	107	41	,	,	PUNCT
aji-173	107	42	feriel	feriel	PROPN
aji-173	107	43	sandra	sandra	PROPN
aji-173	107	44	bouafia	bouafia	PROPN
aji-173	107	45	a	a	PROPN
aji-173	107	46	,	,	PUNCT
aji-173	107	47	boutheina	boutheina	PROPN
aji-173	107	48	abdaoui	abdaoui	PROPN
aji-173	107	49	a	a	PRON
aji-173	107	50	,	,	PUNCT
aji-173	107	51	nacima	nacima	PROPN
aji-173	107	52	sabiha	sabiha	PROPN
aji-173	107	53	gadiri	gadiri	VERB
aji-173	107	54	a	a	PRON
aji-173	107	55	and	and	CCONJ
aji-173	107	56	hichem	hichem	NOUN
aji-173	107	57	frigaa	frigaa	PROPN
aji-173	107	58	b	b	PROPN
aji-173	108	1	a	a	DET
aji-173	108	2	department	department	NOUN
aji-173	108	3	of	of	ADP
aji-173	108	4	immunology	immunology	NOUN
aji-173	108	5	,	,	PUNCT
aji-173	108	6	clinic	clinic	NOUN
aji-173	108	7	sainte	sainte	PROPN
aji-173	108	8	therese	therese	PROPN
aji-173	108	9	uhc	uhc	PROPN
aji-173	108	10	,	,	PUNCT
aji-173	108	11	annaba	annaba	PROPN
aji-173	108	12	,	,	PUNCT
aji-173	108	13	algeria	algeria	PROPN
aji-173	108	14	.	.	PUNCT
aji-173	109	1	b	b	PROPN
aji-173	109	2	department	department	NOUN
aji-173	109	3	of	of	ADP
aji-173	109	4	nephrology	nephrology	NOUN
aji-173	109	5	,	,	PUNCT
aji-173	109	6	hospital	hospital	NOUN
aji-173	109	7	ibn	ibn	PROPN
aji-173	109	8	sina	sina	PROPN
aji-173	109	9	,	,	PUNCT
aji-173	109	10	uhc	uhc	PROPN
aji-173	109	11	,	,	PUNCT
aji-173	109	12	annaba	annaba	PROPN
aji-173	109	13	,	,	PUNCT
aji-173	109	14	algeria	algeria	PROPN
aji-173	109	15	.	.	PUNCT
aji-173	110	1	authors	author	NOUN
aji-173	110	2	’	'	PUNCT
aji-173	110	3	contributions	contribution	NOUN
aji-173	110	4	this	this	DET
aji-173	110	5	work	work	NOUN
aji-173	110	6	was	be	AUX
aji-173	110	7	carried	carry	VERB
aji-173	110	8	out	out	ADP
aji-173	110	9	in	in	ADP
aji-173	110	10	collaboration	collaboration	NOUN
aji-173	110	11	among	among	ADP
aji-173	110	12	all	all	DET
aji-173	110	13	authors	author	NOUN
aji-173	110	14	.	.	PUNCT
aji-173	111	1	all	all	DET
aji-173	111	2	authors	author	NOUN
aji-173	111	3	read	read	VERB
aji-173	111	4	and	and	CCONJ
aji-173	111	5	approved	approve	VERB
aji-173	111	6	the	the	DET
aji-173	111	7	final	final	ADJ
aji-173	111	8	manuscript	manuscript	NOUN
aji-173	111	9	.	.	PUNCT
aji-173	112	1	article	article	NOUN
aji-173	112	2	information	information	PROPN
aji-173	112	3	doi	doi	PROPN
aji-173	112	4	:	:	PUNCT
aji-173	112	5	https://doi.org/10.9734/aji/2025/v8i1173	https://doi.org/10.9734/aji/2025/v8i1173	PROPN
aji-173	112	6	open	open	ADJ
aji-173	112	7	peer	peer	NOUN
aji-173	112	8	review	review	NOUN
aji-173	112	9	history	history	NOUN
aji-173	112	10	:	:	PUNCT
aji-173	112	11	this	this	DET
aji-173	112	12	journal	journal	NOUN
aji-173	112	13	follows	follow	VERB
aji-173	112	14	the	the	DET
aji-173	112	15	advanced	advance	VERB
aji-173	112	16	open	open	ADJ
aji-173	112	17	peer	peer	NOUN
aji-173	112	18	review	review	NOUN
aji-173	112	19	policy	policy	NOUN
aji-173	112	20	.	.	PUNCT
aji-173	113	1	identity	identity	NOUN
aji-173	113	2	of	of	ADP
aji-173	113	3	the	the	DET
aji-173	113	4	reviewers	reviewer	NOUN
aji-173	113	5	,	,	PUNCT
aji-173	113	6	editor(s	editor(s	NOUN
aji-173	113	7	)	)	PUNCT
aji-173	113	8	and	and	CCONJ
aji-173	113	9	additional	additional	ADJ
aji-173	113	10	reviewers	reviewer	NOUN
aji-173	113	11	,	,	PUNCT
aji-173	113	12	peer	peer	NOUN
aji-173	113	13	review	review	NOUN
aji-173	113	14	comments	comment	NOUN
aji-173	113	15	,	,	PUNCT
aji-173	113	16	different	different	ADJ
aji-173	113	17	versions	version	NOUN
aji-173	113	18	of	of	ADP
aji-173	113	19	the	the	DET
aji-173	113	20	manuscript	manuscript	NOUN
aji-173	113	21	,	,	PUNCT
aji-173	113	22	comments	comment	NOUN
aji-173	113	23	of	of	ADP
aji-173	113	24	the	the	DET
aji-173	113	25	editors	editor	NOUN
aji-173	113	26	,	,	PUNCT
aji-173	113	27	etc	etc	X
aji-173	113	28	are	be	AUX
aji-173	113	29	available	available	ADJ
aji-173	113	30	here	here	ADV
aji-173	113	31	:	:	PUNCT
aji-173	113	32	https://pr.sdiarticle5.com/review-history/141940	https://pr.sdiarticle5.com/review-history/141940	NOUN
aji-173	113	33	received	receive	VERB
aji-173	113	34	:	:	PUNCT
aji-173	113	35	10/07/2025	10/07/2025	NUM
aji-173	113	36	published	publish	VERB
aji-173	113	37	:	:	PUNCT
aji-173	113	38	15/09/2025	15/09/2025	NUM
aji-173	113	39	abstract	abstract	ADJ
aji-173	113	40	multiple	multiple	ADJ
aji-173	113	41	myeloma	myeloma	NOUN
aji-173	113	42	(	(	PUNCT
aji-173	113	43	mm	mm	NOUN
aji-173	113	44	)	)	PUNCT
aji-173	113	45	in	in	ADP
aji-173	113	46	pregnant	pregnant	ADJ
aji-173	113	47	women	woman	NOUN
aji-173	113	48	is	be	AUX
aji-173	113	49	a	a	DET
aji-173	113	50	rare	rare	ADJ
aji-173	113	51	disease	disease	NOUN
aji-173	113	52	characterized	characterize	VERB
aji-173	113	53	by	by	ADP
aji-173	113	54	clonal	clonal	ADJ
aji-173	113	55	proliferation	proliferation	NOUN
aji-173	113	56	of	of	ADP
aji-173	113	57	plasma	plasma	NOUN
aji-173	113	58	cells	cell	NOUN
aji-173	113	59	producing	produce	VERB
aji-173	113	60	monoclonal	monoclonal	NOUN
aji-173	113	61	immunoglobulin	immunoglobulin	NOUN
aji-173	113	62	,	,	PUNCT
aji-173	113	63	which	which	PRON
aji-173	113	64	suppresses	suppress	VERB
aji-173	113	65	the	the	DET
aji-173	113	66	normal	normal	ADJ
aji-173	113	67	production	production	NOUN
aji-173	113	68	of	of	ADP
aji-173	113	69	other	other	ADJ
aji-173	113	70	antibodies	antibody	NOUN
aji-173	113	71	and	and	CCONJ
aji-173	113	72	weakens	weaken	VERB
aji-173	113	73	the	the	DET
aji-173	113	74	maternal	maternal	ADJ
aji-173	113	75	immune	immune	ADJ
aji-173	113	76	response	response	NOUN
aji-173	113	77	.	.	PUNCT
aji-173	114	1	plasma	plasma	NOUN
aji-173	114	2	cells	cell	NOUN
aji-173	114	3	release	release	VERB
aji-173	114	4	inflammatory	inflammatory	ADJ
aji-173	114	5	cytokines	cytokine	NOUN
aji-173	114	6	(	(	PUNCT
aji-173	114	7	il-6	il-6	NUM
aji-173	114	8	,	,	PUNCT
aji-173	114	9	tnf	tnf	PROPN
aji-173	114	10	-	-	PUNCT
aji-173	114	11	α	α	PROPN
aji-173	114	12	,	,	PUNCT
aji-173	114	13	il-1β	il-1β	PROPN
aji-173	114	14	)	)	PUNCT
aji-173	114	15	that	that	PRON
aji-173	114	16	promote	promote	VERB
aji-173	114	17	their	their	PRON
aji-173	114	18	survival	survival	NOUN
aji-173	114	19	and	and	CCONJ
aji-173	114	20	bone	bone	NOUN
aji-173	114	21	destruction	destruction	NOUN
aji-173	114	22	.	.	PUNCT
aji-173	115	1	during	during	ADP
aji-173	115	2	pregnancy	pregnancy	NOUN
aji-173	115	3	,	,	PUNCT
aji-173	115	4	maternal	maternal	ADJ
aji-173	115	5	immunity	immunity	NOUN
aji-173	115	6	shifts	shift	NOUN
aji-173	115	7	towards	towards	ADP
aji-173	115	8	complex	complex	ADJ
aji-173	115	9	tolerance	tolerance	NOUN
aji-173	115	10	with	with	ADP
aji-173	115	11	decreased	decrease	VERB
aji-173	115	12	th1	th1	NOUN
aji-173	115	13	inflammatory	inflammatory	ADJ
aji-173	115	14	responses	response	NOUN
aji-173	115	15	,	,	PUNCT
aji-173	115	16	th2	th2	PROPN
aji-173	115	17	predominance	predominance	NOUN
aji-173	115	18	,	,	PUNCT
aji-173	115	19	and	and	CCONJ
aji-173	115	20	increased	increase	VERB
aji-173	115	21	regulatory	regulatory	ADJ
aji-173	115	22	t	t	NOUN
aji-173	115	23	cells	cell	NOUN
aji-173	115	24	,	,	PUNCT
aji-173	115	25	which	which	PRON
aji-173	115	26	often	often	ADV
aji-173	115	27	masks	mask	VERB
aji-173	115	28	mm	mm	PROPN
aji-173	115	29	and	and	CCONJ
aji-173	115	30	complicates	complicate	VERB
aji-173	115	31	its	its	PRON
aji-173	115	32	management	management	NOUN
aji-173	115	33	.	.	PUNCT
aji-173	116	1	treatment	treatment	NOUN
aji-173	116	2	is	be	AUX
aji-173	116	3	generally	generally	ADV
aji-173	116	4	deferred	defer	VERB
aji-173	116	5	until	until	ADP
aji-173	116	6	after	after	ADP
aji-173	116	7	delivery	delivery	NOUN
aji-173	116	8	to	to	PART
aji-173	116	9	protect	protect	VERB
aji-173	116	10	the	the	DET
aji-173	116	11	fetus	fetus	NOUN
aji-173	116	12	,	,	PUNCT
aji-173	116	13	with	with	SCONJ
aji-173	116	14	the	the	DET
aji-173	116	15	vtd	vtd	ADJ
aji-173	116	16	protocol	protocol	NOUN
aji-173	116	17	then	then	ADV
aji-173	116	18	used	use	VERB
aji-173	116	19	to	to	PART
aji-173	116	20	control	control	VERB
aji-173	116	21	the	the	DET
aji-173	116	22	disease	disease	NOUN
aji-173	116	23	by	by	ADP
aji-173	116	24	reducing	reduce	VERB
aji-173	116	25	plasma	plasma	NOUN
aji-173	116	26	cell	cell	NOUN
aji-173	116	27	proliferation	proliferation	NOUN
aji-173	116	28	and	and	CCONJ
aji-173	116	29	inflammation	inflammation	NOUN
aji-173	116	30	.	.	PUNCT
aji-173	117	1	case	case	NOUN
aji-173	117	2	report	report	VERB
aji-173	117	3	https://doi.org/10.9734/aji/2025/v8i1173	https://doi.org/10.9734/aji/2025/v8i1173	PROPN
aji-173	118	1	https://pr.sdiarticle5.com/review-history/141940	https://pr.sdiarticle5.com/review-history/141940	ADJ
aji-173	118	2	meriche	meriche	NOUN
aji-173	118	3	et	et	PROPN
aji-173	118	4	al	al	PROPN
aji-173	118	5	.	.	PROPN
aji-173	118	6	;	;	PUNCT
aji-173	118	7	asian	asian	PROPN
aji-173	118	8	j.	j.	PROPN
aji-173	118	9	immunol	immunol	PROPN
aji-173	118	10	.	.	PROPN
aji-173	118	11	,	,	PUNCT
aji-173	118	12	vol	vol	NOUN
aji-173	118	13	.	.	PROPN
aji-173	118	14	8	8	NUM
aji-173	118	15	,	,	PUNCT
aji-173	118	16	no	no	INTJ
aji-173	118	17	.	.	NOUN
aji-173	118	18	1	1	NUM
aji-173	118	19	,	,	PUNCT
aji-173	118	20	pp	pp	ADJ
aji-173	118	21	.	.	PUNCT
aji-173	119	1	222	222	NUM
aji-173	119	2	-	-	SYM
aji-173	119	3	229	229	NUM
aji-173	119	4	,	,	PUNCT
aji-173	119	5	2025	2025	NUM
aji-173	119	6	;	;	PUNCT
aji-173	119	7	article	article	NOUN
aji-173	119	8	no.aji.141940	no.aji.141940	NOUN
aji-173	119	9	223	223	NUM
aji-173	119	10	this	this	DET
aji-173	119	11	case	case	NOUN
aji-173	119	12	illustrates	illustrate	VERB
aji-173	119	13	the	the	DET
aji-173	119	14	importance	importance	NOUN
aji-173	119	15	of	of	ADP
aji-173	119	16	simple	simple	ADJ
aji-173	119	17	tests	test	NOUN
aji-173	119	18	such	such	ADJ
aji-173	119	19	as	as	ADP
aji-173	119	20	serum	serum	NOUN
aji-173	119	21	protein	protein	NOUN
aji-173	119	22	electrophoresis	electrophoresis	NOUN
aji-173	119	23	in	in	ADP
aji-173	119	24	diagnosing	diagnose	VERB
aji-173	119	25	unexplained	unexplained	ADJ
aji-173	119	26	anemia	anemia	NOUN
aji-173	119	27	during	during	ADP
aji-173	119	28	pregnancy	pregnancy	NOUN
aji-173	119	29	,	,	PUNCT
aji-173	119	30	and	and	CCONJ
aji-173	119	31	highlights	highlight	VERB
aji-173	119	32	the	the	DET
aji-173	119	33	need	need	NOUN
aji-173	119	34	for	for	ADP
aji-173	119	35	immunological	immunological	ADJ
aji-173	119	36	monitoring	monitoring	NOUN
aji-173	119	37	and	and	CCONJ
aji-173	119	38	a	a	DET
aji-173	119	39	multidisciplinary	multidisciplinary	ADJ
aji-173	119	40	approach	approach	NOUN
aji-173	119	41	to	to	PART
aji-173	119	42	optimize	optimize	VERB
aji-173	119	43	maternal	maternal	ADJ
aji-173	119	44	and	and	CCONJ
aji-173	119	45	fetal	fetal	ADJ
aji-173	119	46	prognosis	prognosis	NOUN
aji-173	119	47	.	.	PUNCT
aji-173	120	1	keywords	keyword	NOUN
aji-173	120	2	:	:	PUNCT
aji-173	120	3	multiple	multiple	ADJ
aji-173	120	4	myeloma	myeloma	NOUN
aji-173	120	5	;	;	PUNCT
aji-173	120	6	pregnancy	pregnancy	NOUN
aji-173	120	7	;	;	PUNCT
aji-173	120	8	anemia	anemia	NOUN
aji-173	120	9	;	;	PUNCT
aji-173	120	10	monoclonal	monoclonal	NOUN
aji-173	120	11	composant	composant	NOUN
aji-173	120	12	;	;	PUNCT
aji-173	120	13	electrophoresis	electrophoresi	NOUN
aji-173	120	14	.	.	NOUN
aji-173	121	1	1	1	X
aji-173	121	2	.	.	X
aji-173	121	3	introduction	introduction	NOUN
aji-173	121	4	multiple	multiple	ADJ
aji-173	121	5	myeloma	myeloma	NOUN
aji-173	121	6	is	be	AUX
aji-173	121	7	a	a	DET
aji-173	121	8	malignant	malignant	ADJ
aji-173	121	9	clonal	clonal	ADJ
aji-173	121	10	proliferation	proliferation	NOUN
aji-173	121	11	of	of	ADP
aji-173	121	12	plasma	plasma	NOUN
aji-173	121	13	cells	cell	NOUN
aji-173	121	14	characterized	characterize	VERB
aji-173	121	15	by	by	ADP
aji-173	121	16	excessive	excessive	ADJ
aji-173	121	17	monoclonal	monoclonal	NOUN
aji-173	121	18	production	production	NOUN
aji-173	121	19	of	of	ADP
aji-173	121	20	immunoglobulins	immunoglobulin	NOUN
aji-173	121	21	,	,	PUNCT
aji-173	121	22	mainly	mainly	ADV
aji-173	121	23	igg	igg	PROPN
aji-173	121	24	.	.	PUNCT
aji-173	122	1	the	the	DET
aji-173	122	2	median	median	ADJ
aji-173	122	3	age	age	NOUN
aji-173	122	4	at	at	ADP
aji-173	122	5	diagnosis	diagnosis	NOUN
aji-173	122	6	is	be	AUX
aji-173	122	7	generally	generally	ADV
aji-173	122	8	around	around	ADP
aji-173	122	9	63	63	NUM
aji-173	122	10	to	to	PART
aji-173	122	11	70	70	NUM
aji-173	122	12	years	year	NOUN
aji-173	122	13	,	,	PUNCT
aji-173	122	14	with	with	ADP
aji-173	122	15	cases	case	NOUN
aji-173	122	16	in	in	ADP
aji-173	122	17	young	young	ADJ
aji-173	122	18	people	people	NOUN
aji-173	122	19	,	,	PUNCT
aji-173	122	20	and	and	CCONJ
aji-173	122	21	particularly	particularly	ADV
aji-173	122	22	during	during	ADP
aji-173	122	23	pregnancy	pregnancy	NOUN
aji-173	122	24	,	,	PUNCT
aji-173	122	25	remaining	remain	VERB
aji-173	122	26	extremely	extremely	ADV
aji-173	122	27	rare	rare	ADJ
aji-173	122	28	,	,	PUNCT
aji-173	122	29	with	with	ADP
aji-173	122	30	fewer	few	ADJ
aji-173	122	31	than	than	ADP
aji-173	122	32	50	50	NUM
aji-173	122	33	cases	case	NOUN
aji-173	122	34	described	describe	VERB
aji-173	122	35	in	in	ADP
aji-173	122	36	the	the	DET
aji-173	122	37	global	global	ADJ
aji-173	122	38	literature	literature	NOUN
aji-173	122	39	since	since	SCONJ
aji-173	122	40	1965	1965	NUM
aji-173	122	41	(	(	PUNCT
aji-173	122	42	durand	durand	NOUN
aji-173	122	43	,	,	PUNCT
aji-173	122	44	2024	2024	NUM
aji-173	122	45	;	;	PUNCT
aji-173	122	46	hila	hila	PROPN
aji-173	122	47	et	et	PROPN
aji-173	122	48	al	al	PROPN
aji-173	122	49	.	.	PROPN
aji-173	122	50	2022	2022	NUM
aji-173	122	51	)	)	PUNCT
aji-173	122	52	.	.	PUNCT
aji-173	123	1	myeloma	myeloma	NOUN
aji-173	123	2	in	in	ADP
aji-173	123	3	pregnancy	pregnancy	NOUN
aji-173	123	4	is	be	AUX
aji-173	123	5	a	a	DET
aji-173	123	6	rare	rare	ADJ
aji-173	123	7	occurrence	occurrence	NOUN
aji-173	123	8	as	as	ADP
aji-173	123	9	the	the	DET
aji-173	123	10	median	median	ADJ
aji-173	123	11	age	age	NOUN
aji-173	123	12	of	of	ADP
aji-173	123	13	myeloma	myeloma	NOUN
aji-173	123	14	diagnosis	diagnosis	NOUN
aji-173	123	15	is	be	AUX
aji-173	123	16	around	around	ADP
aji-173	123	17	the	the	DET
aji-173	123	18	sixth	sixth	ADJ
aji-173	123	19	and	and	CCONJ
aji-173	123	20	seventh	seventh	ADJ
aji-173	123	21	decade	decade	NOUN
aji-173	123	22	of	of	ADP
aji-173	123	23	life	life	NOUN
aji-173	123	24	and	and	CCONJ
aji-173	123	25	is	be	AUX
aji-173	123	26	more	more	ADV
aji-173	123	27	commonly	commonly	ADV
aji-173	123	28	observed	observe	VERB
aji-173	123	29	in	in	ADP
aji-173	123	30	males	male	NOUN
aji-173	123	31	.	.	PUNCT
aji-173	124	1	the	the	DET
aji-173	124	2	first	first	ADJ
aji-173	124	3	case	case	NOUN
aji-173	124	4	of	of	ADP
aji-173	124	5	myeloma	myeloma	NOUN
aji-173	124	6	in	in	ADP
aji-173	124	7	pregnancy	pregnancy	NOUN
aji-173	124	8	was	be	AUX
aji-173	124	9	reported	report	VERB
aji-173	124	10	in	in	ADP
aji-173	124	11	1965	1965	NUM
aji-173	124	12	,	,	PUNCT
aji-173	124	13	and	and	CCONJ
aji-173	124	14	since	since	SCONJ
aji-173	124	15	then	then	ADV
aji-173	124	16	there	there	PRON
aji-173	124	17	have	have	AUX
aji-173	124	18	been	be	AUX
aji-173	124	19	fewer	few	ADJ
aji-173	124	20	than	than	ADP
aji-173	124	21	fifty	fifty	NUM
aji-173	124	22	cases	case	NOUN
aji-173	124	23	reported	report	VERB
aji-173	124	24	worldwide	worldwide	ADV
aji-173	124	25	.	.	PUNCT
aji-173	125	1	although	although	SCONJ
aji-173	125	2	only	only	ADV
aji-173	125	3	three	three	NUM
aji-173	125	4	percent	percent	NOUN
aji-173	125	5	of	of	ADP
aji-173	125	6	cases	case	NOUN
aji-173	125	7	are	be	AUX
aji-173	125	8	diagnosed	diagnose	VERB
aji-173	125	9	below	below	ADP
aji-173	125	10	the	the	DET
aji-173	125	11	age	age	NOUN
aji-173	125	12	of	of	ADP
aji-173	125	13	forty	forty	NUM
aji-173	125	14	,	,	PUNCT
aji-173	125	15	myeloma	myeloma	PROPN
aji-173	125	16	is	be	AUX
aji-173	125	17	now	now	ADV
aji-173	125	18	increasingly	increasingly	ADV
aji-173	125	19	being	be	AUX
aji-173	125	20	diagnosed	diagnose	VERB
aji-173	125	21	in	in	ADP
aji-173	125	22	younger	young	ADJ
aji-173	125	23	ages	age	NOUN
aji-173	125	24	and	and	CCONJ
aji-173	125	25	during	during	ADP
aji-173	125	26	pregnancy	pregnancy	NOUN
aji-173	125	27	due	due	ADP
aji-173	125	28	to	to	ADP
aji-173	125	29	better	well	ADJ
aji-173	125	30	screening	screening	NOUN
aji-173	125	31	and	and	CCONJ
aji-173	125	32	awareness	awareness	NOUN
aji-173	125	33	(	(	PUNCT
aji-173	125	34	szydełko	szydełko	NOUN
aji-173	125	35	,	,	PUNCT
aji-173	125	36	2019	2019	NUM
aji-173	125	37	)	)	PUNCT
aji-173	125	38	.	.	PUNCT
aji-173	126	1	gestational	gestational	ADJ
aji-173	126	2	anemia	anemia	NOUN
aji-173	126	3	is	be	AUX
aji-173	126	4	common	common	ADJ
aji-173	126	5	,	,	PUNCT
aji-173	126	6	but	but	CCONJ
aji-173	126	7	in	in	ADP
aji-173	126	8	the	the	DET
aji-173	126	9	presence	presence	NOUN
aji-173	126	10	of	of	ADP
aji-173	126	11	a	a	DET
aji-173	126	12	monoclonal	monoclonal	NOUN
aji-173	126	13	peak	peak	NOUN
aji-173	126	14	,	,	PUNCT
aji-173	126	15	further	further	ADJ
aji-173	126	16	investigation	investigation	NOUN
aji-173	126	17	is	be	AUX
aji-173	126	18	necessary	necessary	ADJ
aji-173	126	19	to	to	PART
aji-173	126	20	rule	rule	VERB
aji-173	126	21	out	out	ADP
aji-173	126	22	an	an	DET
aji-173	126	23	underlying	underlie	VERB
aji-173	126	24	blood	blood	NOUN
aji-173	126	25	disorder	disorder	NOUN
aji-173	126	26	and	and	CCONJ
aji-173	126	27	ensure	ensure	VERB
aji-173	126	28	appropriate	appropriate	ADJ
aji-173	126	29	management	management	NOUN
aji-173	126	30	.	.	PUNCT
aji-173	127	1	however	however	ADV
aji-173	127	2	,	,	PUNCT
aji-173	127	3	diagnosis	diagnosis	NOUN
aji-173	127	4	is	be	AUX
aji-173	127	5	complicated	complicate	VERB
aji-173	127	6	by	by	ADP
aji-173	127	7	the	the	DET
aji-173	127	8	overlap	overlap	NOUN
aji-173	127	9	with	with	ADP
aji-173	127	10	the	the	DET
aji-173	127	11	physiological	physiological	ADJ
aji-173	127	12	symptoms	symptom	NOUN
aji-173	127	13	of	of	ADP
aji-173	127	14	pregnancy	pregnancy	NOUN
aji-173	127	15	.	.	PUNCT
aji-173	128	1	therefore	therefore	ADV
aji-173	128	2	,	,	PUNCT
aji-173	128	3	particular	particular	ADJ
aji-173	128	4	vigilance	vigilance	NOUN
aji-173	128	5	is	be	AUX
aji-173	128	6	required	require	VERB
aji-173	128	7	.	.	PUNCT
aji-173	129	1	2	2	X
aji-173	129	2	.	.	X
aji-173	129	3	case	case	NOUN
aji-173	129	4	presentation	presentation	NOUN
aji-173	129	5	a	a	DET
aji-173	129	6	35	35	NUM
aji-173	129	7	-	-	PUNCT
aji-173	129	8	year	year	NOUN
aji-173	129	9	-	-	PUNCT
aji-173	129	10	old	old	ADJ
aji-173	129	11	patient	patient	NOUN
aji-173	129	12	from	from	ADP
aji-173	129	13	annaba	annaba	PROPN
aji-173	129	14	(	(	PUNCT
aji-173	129	15	algeria	algeria	PROPN
aji-173	129	16	)	)	PUNCT
aji-173	129	17	,	,	PUNCT
aji-173	129	18	24	24	NUM
aji-173	129	19	weeks	week	NOUN
aji-173	129	20	pregnant	pregnant	ADJ
aji-173	129	21	with	with	ADP
aji-173	129	22	her	her	PRON
aji-173	129	23	second	second	ADJ
aji-173	129	24	child	child	NOUN
aji-173	129	25	,	,	PUNCT
aji-173	129	26	with	with	ADP
aji-173	129	27	no	no	DET
aji-173	129	28	notable	notable	ADJ
aji-173	129	29	family	family	NOUN
aji-173	129	30	history	history	NOUN
aji-173	129	31	.	.	PUNCT
aji-173	130	1	she	she	PRON
aji-173	130	2	complains	complain	VERB
aji-173	130	3	of	of	ADP
aji-173	130	4	persistent	persistent	ADJ
aji-173	130	5	fatigue	fatigue	NOUN
aji-173	130	6	accompanied	accompany	VERB
aji-173	130	7	by	by	ADP
aji-173	130	8	pale	pale	ADJ
aji-173	130	9	skin	skin	NOUN
aji-173	130	10	.	.	PUNCT
aji-173	131	1	clinical	clinical	ADJ
aji-173	131	2	examination	examination	NOUN
aji-173	131	3	revealed	reveal	VERB
aji-173	131	4	marked	mark	VERB
aji-173	131	5	pallor	pallor	NOUN
aji-173	131	6	,	,	PUNCT
aji-173	131	7	a	a	DET
aji-173	131	8	uterine	uterine	ADJ
aji-173	131	9	fundus	fundus	NOUN
aji-173	131	10	consistent	consistent	ADJ
aji-173	131	11	with	with	ADP
aji-173	131	12	24	24	NUM
aji-173	131	13	weeks	week	NOUN
aji-173	131	14	,	,	PUNCT
aji-173	131	15	a	a	DET
aji-173	131	16	normal	normal	ADJ
aji-173	131	17	fetal	fetal	ADJ
aji-173	131	18	heart	heart	NOUN
aji-173	131	19	rate	rate	NOUN
aji-173	131	20	(	(	PUNCT
aji-173	131	21	140	140	NUM
aji-173	131	22	bpm	bpm	NOUN
aji-173	131	23	)	)	PUNCT
aji-173	131	24	,	,	PUNCT
aji-173	131	25	and	and	CCONJ
aji-173	131	26	a	a	DET
aji-173	131	27	high	high	ADJ
aji-173	131	28	body	body	NOUN
aji-173	131	29	mass	mass	NOUN
aji-173	131	30	index	index	NOUN
aji-173	131	31	of	of	ADP
aji-173	131	32	28	28	NUM
aji-173	131	33	kg	kg	NOUN
aji-173	131	34	/	/	SYM
aji-173	131	35	m²	m²	PROPN
aji-173	131	36	.	.	PUNCT
aji-173	132	1	blood	blood	NOUN
aji-173	132	2	pressure	pressure	NOUN
aji-173	132	3	was	be	AUX
aji-173	132	4	stable	stable	ADJ
aji-173	132	5	at	at	ADP
aji-173	132	6	120/80	120/80	NUM
aji-173	132	7	mmhg	mmhg	NOUN
aji-173	132	8	.	.	PUNCT
aji-173	133	1	2.1	2.1	NUM
aji-173	133	2	biological	biological	ADJ
aji-173	133	3	and	and	CCONJ
aji-173	133	4	hematological	hematological	ADJ
aji-173	133	5	tests	test	NOUN
aji-173	133	6	blood	blood	NOUN
aji-173	133	7	count	count	NOUN
aji-173	133	8	reveals	reveal	VERB
aji-173	133	9	moderate	moderate	ADJ
aji-173	133	10	anemia	anemia	NOUN
aji-173	133	11	(	(	PUNCT
aji-173	133	12	hb	hb	PROPN
aji-173	133	13	10	10	NUM
aji-173	133	14	g	g	PROPN
aji-173	133	15	/	/	SYM
aji-173	133	16	dl	dl	PROPN
aji-173	133	17	,	,	PUNCT
aji-173	133	18	hematocrit	hematocrit	ADJ
aji-173	133	19	30	30	NUM
aji-173	133	20	%	%	NOUN
aji-173	133	21	,	,	PUNCT
aji-173	133	22	mcv	mcv	PROPN
aji-173	133	23	75	75	NUM
aji-173	133	24	fl	fl	NOUN
aji-173	133	25	)	)	PUNCT
aji-173	133	26	,	,	PUNCT
aji-173	133	27	associated	associate	VERB
aji-173	133	28	with	with	ADP
aji-173	133	29	low	low	ADJ
aji-173	133	30	ferritin	ferritin	ADJ
aji-173	133	31	(	(	PUNCT
aji-173	133	32	22	22	NUM
aji-173	133	33	ng	ng	PROPN
aji-173	133	34	/	/	SYM
aji-173	133	35	ml	ml	NOUN
aji-173	133	36	)	)	PUNCT
aji-173	133	37	indicative	indicative	ADJ
aji-173	133	38	of	of	ADP
aji-173	133	39	probable	probable	ADJ
aji-173	133	40	iron	iron	NOUN
aji-173	133	41	deficiency	deficiency	NOUN
aji-173	133	42	.	.	PUNCT
aji-173	134	1	blood	blood	NOUN
aji-173	134	2	smear	smear	NOUN
aji-173	134	3	shows	show	VERB
aji-173	134	4	anisocytosis	anisocytosis	NOUN
aji-173	134	5	,	,	PUNCT
aji-173	134	6	polychromatophilia	polychromatophilia	NOUN
aji-173	134	7	,	,	PUNCT
aji-173	134	8	presence	presence	NOUN
aji-173	134	9	of	of	ADP
aji-173	134	10	erythroblasts	erythroblast	NOUN
aji-173	134	11	,	,	PUNCT
aji-173	134	12	neutrophilic	neutrophilic	ADJ
aji-173	134	13	hyperleukocytosis	hyperleukocytosis	NOUN
aji-173	134	14	with	with	ADP
aji-173	134	15	coarse	coarse	NOUN
aji-173	134	16	granulations	granulation	NOUN
aji-173	134	17	,	,	PUNCT
aji-173	134	18	and	and	CCONJ
aji-173	134	19	moderate	moderate	ADJ
aji-173	134	20	thrombocytopenia	thrombocytopenia	PROPN
aji-173	134	21	.	.	PUNCT
aji-173	135	1	the	the	DET
aji-173	135	2	sedimentation	sedimentation	NOUN
aji-173	135	3	rate	rate	NOUN
aji-173	135	4	was	be	AUX
aji-173	135	5	accelerated	accelerate	VERB
aji-173	135	6	(	(	PUNCT
aji-173	135	7	78	78	NUM
aji-173	135	8	mm	mm	NOUN
aji-173	135	9	/	/	SYM
aji-173	135	10	h	h	NOUN
aji-173	135	11	)	)	PUNCT
aji-173	135	12	.	.	PUNCT
aji-173	136	1	serum	serum	NOUN
aji-173	136	2	protein	protein	NOUN
aji-173	136	3	electrophoresis	electrophoresis	NOUN
aji-173	136	4	(	(	PUNCT
aji-173	136	5	sebia	sebia	ADV
aji-173	136	6	)	)	PUNCT
aji-173	136	7	revealed	reveal	VERB
aji-173	136	8	a	a	DET
aji-173	136	9	monoclonal	monoclonal	NOUN
aji-173	136	10	igg	igg	PROPN
aji-173	136	11	kappa	kappa	PROPN
aji-173	136	12	peak	peak	PROPN
aji-173	136	13	of	of	ADP
aji-173	136	14	42	42	NUM
aji-173	136	15	g	g	NOUN
aji-173	136	16	/	/	SYM
aji-173	136	17	l	l	NOUN
aji-173	136	18	,	,	PUNCT
aji-173	136	19	confirmed	confirm	VERB
aji-173	136	20	by	by	ADP
aji-173	136	21	immunofixation	immunofixation	NOUN
aji-173	136	22	.	.	PUNCT
aji-173	137	1	serum	serum	PROPN
aji-173	137	2	free	free	ADJ
aji-173	137	3	light	light	NOUN
aji-173	137	4	chain	chain	NOUN
aji-173	137	5	assay	assay	NOUN
aji-173	137	6	(	(	PUNCT
aji-173	137	7	sebia	sebia	ADV
aji-173	137	8	)	)	PUNCT
aji-173	137	9	showed	show	VERB
aji-173	137	10	a	a	DET
aji-173	137	11	high	high	ADJ
aji-173	137	12	κ	κ	NOUN
aji-173	137	13	/	/	SYM
aji-173	137	14	λ	λ	NOUN
aji-173	137	15	ratio	ratio	NOUN
aji-173	137	16	(	(	PUNCT
aji-173	137	17	3.86	3.86	NUM
aji-173	137	18	)	)	PUNCT
aji-173	137	19	.	.	PUNCT
aji-173	138	1	bence	bence	PROPN
aji-173	138	2	jones	jones	PROPN
aji-173	138	3	proteinuria	proteinuria	PROPN
aji-173	138	4	was	be	AUX
aji-173	138	5	positive	positive	ADJ
aji-173	138	6	.	.	PUNCT
aji-173	139	1	in	in	ADP
aji-173	139	2	addition	addition	NOUN
aji-173	139	3	,	,	PUNCT
aji-173	139	4	mild	mild	ADJ
aji-173	139	5	renal	renal	ADJ
aji-173	139	6	failure	failure	NOUN
aji-173	139	7	is	be	AUX
aji-173	139	8	observed	observe	VERB
aji-173	139	9	with	with	ADP
aji-173	139	10	a	a	DET
aji-173	139	11	slight	slight	ADJ
aji-173	139	12	increase	increase	NOUN
aji-173	139	13	in	in	ADP
aji-173	139	14	urea	urea	NOUN
aji-173	139	15	(	(	PUNCT
aji-173	139	16	9.8	9.8	NUM
aji-173	139	17	mmol	mmol	NOUN
aji-173	139	18	/	/	SYM
aji-173	139	19	l	l	NOUN
aji-173	139	20	)	)	PUNCT
aji-173	139	21	,	,	PUNCT
aji-173	139	22	creatinine	creatinine	NOUN
aji-173	139	23	(	(	PUNCT
aji-173	139	24	165	165	NUM
aji-173	139	25	µmol	µmol	NOUN
aji-173	139	26	/	/	SYM
aji-173	139	27	l	l	NOUN
aji-173	139	28	)	)	PUNCT
aji-173	139	29	,	,	PUNCT
aji-173	139	30	and	and	CCONJ
aji-173	139	31	proteinuria	proteinuria	NOUN
aji-173	139	32	at	at	ADP
aji-173	139	33	650	650	NUM
aji-173	139	34	mg/24h	mg/24h	NOUN
aji-173	139	35	.	.	PUNCT
aji-173	140	1	moderate	moderate	ADJ
aji-173	140	2	hypercalcemia	hypercalcemia	NOUN
aji-173	140	3	(	(	PUNCT
aji-173	140	4	2.85	2.85	NUM
aji-173	140	5	mmol	mmol	NOUN
aji-173	140	6	/	/	SYM
aji-173	140	7	l	l	NOUN
aji-173	140	8	)	)	PUNCT
aji-173	140	9	and	and	CCONJ
aji-173	140	10	a	a	DET
aji-173	140	11	liver	liver	NOUN
aji-173	140	12	profile	profile	NOUN
aji-173	140	13	consistent	consistent	ADJ
aji-173	140	14	with	with	ADP
aji-173	140	15	pregnancy	pregnancy	NOUN
aji-173	140	16	-	-	PUNCT
aji-173	140	17	related	relate	VERB
aji-173	140	18	cholestasis	cholestasis	NOUN
aji-173	140	19	complete	complete	ADJ
aji-173	140	20	the	the	DET
aji-173	140	21	picture	picture	NOUN
aji-173	140	22	(	(	PUNCT
aji-173	140	23	figs	fig	NOUN
aji-173	140	24	.	.	PUNCT
aji-173	141	1	1	1	NUM
aji-173	141	2	,	,	PUNCT
aji-173	141	3	2	2	NUM
aji-173	141	4	,	,	PUNCT
aji-173	141	5	3	3	NUM
aji-173	141	6	)	)	PUNCT
aji-173	141	7	.	.	PUNCT
aji-173	142	1	2.2	2.2	NUM
aji-173	142	2	morphological	morphological	ADJ
aji-173	142	3	and	and	CCONJ
aji-173	142	4	radiological	radiological	ADJ
aji-173	142	5	examinations	examination	NOUN
aji-173	142	6	the	the	DET
aji-173	142	7	bone	bone	NOUN
aji-173	142	8	marrow	marrow	NOUN
aji-173	142	9	aspiration	aspiration	NOUN
aji-173	142	10	revealed	reveal	VERB
aji-173	142	11	significant	significant	ADJ
aji-173	142	12	plasma	plasma	NOUN
aji-173	142	13	cell	cell	NOUN
aji-173	142	14	infiltration	infiltration	NOUN
aji-173	142	15	estimated	estimate	VERB
aji-173	142	16	at	at	ADP
aji-173	142	17	65	65	NUM
aji-173	142	18	%	%	NOUN
aji-173	142	19	,	,	PUNCT
aji-173	142	20	which	which	PRON
aji-173	142	21	was	be	AUX
aji-173	142	22	confirmed	confirm	VERB
aji-173	142	23	as	as	ADP
aji-173	142	24	clonal	clonal	ADJ
aji-173	142	25	by	by	ADP
aji-173	142	26	immunophenotyping	immunophenotype	VERB
aji-173	142	27	(	(	PUNCT
aji-173	142	28	cd38	cd38	PROPN
aji-173	142	29	+	+	PROPN
aji-173	142	30	,	,	PUNCT
aji-173	142	31	cd138	cd138	PROPN
aji-173	142	32	+	+	PROPN
aji-173	142	33	,	,	PUNCT
aji-173	142	34	cd56	cd56	PROPN
aji-173	142	35	+	+	PROPN
aji-173	142	36	)	)	PUNCT
aji-173	142	37	using	use	VERB
aji-173	142	38	flow	flow	NOUN
aji-173	142	39	cytometry	cytometry	NOUN
aji-173	142	40	(	(	PUNCT
aji-173	142	41	bd	bd	PROPN
aji-173	142	42	facs	facs	PROPN
aji-173	142	43	lyric	lyric	NOUN
aji-173	142	44	)	)	PUNCT
aji-173	142	45	.	.	PUNCT
aji-173	143	1	a	a	DET
aji-173	143	2	low	low	ADV
aji-173	143	3	-	-	PUNCT
aji-173	143	4	dose	dose	NOUN
aji-173	143	5	whole	whole	ADJ
aji-173	143	6	-	-	PUNCT
aji-173	143	7	body	body	NOUN
aji-173	143	8	ct	ct	PROPN
aji-173	143	9	scan	scan	NOUN
aji-173	143	10	detected	detect	VERB
aji-173	143	11	a	a	DET
aji-173	143	12	6	6	NUM
aji-173	143	13	mm	mm	NOUN
aji-173	143	14	osteolytic	osteolytic	ADJ
aji-173	143	15	lesion	lesion	NOUN
aji-173	143	16	in	in	ADP
aji-173	143	17	the	the	DET
aji-173	143	18	pelvis	pelvis	NOUN
aji-173	143	19	,	,	PUNCT
aji-173	143	20	typical	typical	ADJ
aji-173	143	21	of	of	ADP
aji-173	143	22	bone	bone	NOUN
aji-173	143	23	involvement	involvement	NOUN
aji-173	143	24	associated	associate	VERB
aji-173	143	25	with	with	ADP
aji-173	143	26	multiple	multiple	ADJ
aji-173	143	27	myeloma	myeloma	NOUN
aji-173	143	28	.	.	PUNCT
aji-173	144	1	abdominal	abdominal	ADJ
aji-173	144	2	and	and	CCONJ
aji-173	144	3	obstetric	obstetric	ADJ
aji-173	144	4	ultrasounds	ultrasound	NOUN
aji-173	144	5	showed	show	VERB
aji-173	144	6	a	a	DET
aji-173	144	7	normal	normal	ADJ
aji-173	144	8	fetus	fetus	NOUN
aji-173	144	9	with	with	ADP
aji-173	144	10	no	no	DET
aji-173	144	11	abnormalities	abnormality	NOUN
aji-173	144	12	or	or	CCONJ
aji-173	144	13	growth	growth	NOUN
aji-173	144	14	retardation	retardation	NOUN
aji-173	144	15	,	,	PUNCT
aji-173	144	16	and	and	CCONJ
aji-173	144	17	measurements	measurement	NOUN
aji-173	144	18	were	be	AUX
aji-173	144	19	within	within	ADP
aji-173	144	20	normal	normal	ADJ
aji-173	144	21	limits	limit	NOUN
aji-173	144	22	.	.	PUNCT
aji-173	145	1	these	these	DET
aji-173	145	2	examinations	examination	NOUN
aji-173	145	3	,	,	PUNCT
aji-173	145	4	which	which	PRON
aji-173	145	5	limit	limit	VERB
aji-173	145	6	fetal	fetal	ADJ
aji-173	145	7	exposure	exposure	NOUN
aji-173	145	8	to	to	ADP
aji-173	145	9	radiation	radiation	NOUN
aji-173	145	10	,	,	PUNCT
aji-173	145	11	are	be	AUX
aji-173	145	12	essential	essential	ADJ
aji-173	145	13	for	for	ADP
aji-173	145	14	assessing	assess	VERB
aji-173	145	15	the	the	DET
aji-173	145	16	extent	extent	NOUN
aji-173	145	17	of	of	ADP
aji-173	145	18	the	the	DET
aji-173	145	19	disease	disease	NOUN
aji-173	145	20	while	while	SCONJ
aji-173	145	21	ensuring	ensure	VERB
aji-173	145	22	safe	safe	ADJ
aji-173	145	23	,	,	PUNCT
aji-173	145	24	risk	risk	NOUN
aji-173	145	25	-	-	PUNCT
aji-173	145	26	free	free	ADJ
aji-173	145	27	maternal	maternal	ADJ
aji-173	145	28	-	-	PUNCT
aji-173	145	29	fetal	fetal	ADJ
aji-173	145	30	monitoring	monitoring	NOUN
aji-173	145	31	.	.	PUNCT
aji-173	146	1	2.3	2.3	NUM
aji-173	146	2	diagnosis	diagnosis	NOUN
aji-173	146	3	the	the	DET
aji-173	146	4	diagnosis	diagnosis	NOUN
aji-173	146	5	of	of	ADP
aji-173	146	6	symptomatic	symptomatic	ADJ
aji-173	146	7	multiple	multiple	ADJ
aji-173	146	8	myeloma	myeloma	NOUN
aji-173	146	9	in	in	ADP
aji-173	146	10	the	the	DET
aji-173	146	11	patient	patient	NOUN
aji-173	146	12	was	be	AUX
aji-173	146	13	based	base	VERB
aji-173	146	14	on	on	ADP
aji-173	146	15	the	the	DET
aji-173	146	16	combination	combination	NOUN
aji-173	146	17	of	of	ADP
aji-173	146	18	a	a	DET
aji-173	146	19	significant	significant	ADJ
aji-173	146	20	monoclonal	monoclonal	NOUN
aji-173	146	21	igg	igg	PROPN
aji-173	146	22	kappa	kappa	PROPN
aji-173	146	23	peak	peak	PROPN
aji-173	146	24	associated	associate	VERB
aji-173	146	25	with	with	ADP
aji-173	146	26	a	a	DET
aji-173	146	27	high	high	ADJ
aji-173	146	28	κ	κ	NOUN
aji-173	146	29	/	/	SYM
aji-173	146	30	λ	λ	NOUN
aji-173	146	31	ratio	ratio	NOUN
aji-173	146	32	,	,	PUNCT
aji-173	146	33	with	with	ADP
aji-173	146	34	positive	positive	ADJ
aji-173	146	35	bence	bence	NOUN
aji-173	146	36	jones	jones	PROPN
aji-173	146	37	proteinuria	proteinuria	PROPN
aji-173	146	38	indicating	indicate	VERB
aji-173	146	39	significant	significant	ADJ
aji-173	146	40	renal	renal	ADJ
aji-173	146	41	involvement	involvement	NOUN
aji-173	146	42	,	,	PUNCT
aji-173	146	43	as	as	ADV
aji-173	146	44	well	well	ADV
aji-173	146	45	as	as	ADP
aji-173	146	46	high	high	ADJ
aji-173	146	47	myeloid	myeloid	ADJ
aji-173	146	48	plasma	plasma	NOUN
aji-173	146	49	cell	cell	NOUN
aji-173	146	50	infiltration	infiltration	NOUN
aji-173	146	51	(	(	PUNCT
aji-173	146	52	65	65	NUM
aji-173	146	53	%	%	NOUN
aji-173	146	54	)	)	PUNCT
aji-173	146	55	with	with	ADP
aji-173	146	56	characteristic	characteristic	ADJ
aji-173	146	57	immunophenotyping	immunophenotyping	NOUN
aji-173	146	58	(	(	PUNCT
aji-173	146	59	cd38	cd38	PROPN
aji-173	146	60	+	+	PROPN
aji-173	146	61	,	,	PUNCT
aji-173	146	62	cd138	cd138	PROPN
aji-173	146	63	+	+	PROPN
aji-173	146	64	,	,	PUNCT
aji-173	146	65	cd56	cd56	PROPN
aji-173	146	66	+	+	PROPN
aji-173	146	67	)	)	PUNCT
aji-173	146	68	.	.	PUNCT
aji-173	147	1	meriche	meriche	NOUN
aji-173	147	2	et	et	PROPN
aji-173	147	3	al	al	PROPN
aji-173	147	4	.	.	PROPN
aji-173	147	5	;	;	PUNCT
aji-173	147	6	asian	asian	PROPN
aji-173	147	7	j.	j.	PROPN
aji-173	147	8	immunol	immunol	PROPN
aji-173	147	9	.	.	PROPN
aji-173	147	10	,	,	PUNCT
aji-173	147	11	vol	vol	NOUN
aji-173	147	12	.	.	PROPN
aji-173	147	13	8	8	NUM
aji-173	147	14	,	,	PUNCT
aji-173	147	15	no	no	INTJ
aji-173	147	16	.	.	NOUN
aji-173	147	17	1	1	NUM
aji-173	147	18	,	,	PUNCT
aji-173	147	19	pp	pp	ADJ
aji-173	147	20	.	.	PUNCT
aji-173	148	1	222	222	NUM
aji-173	148	2	-	-	SYM
aji-173	148	3	229	229	NUM
aji-173	148	4	,	,	PUNCT
aji-173	148	5	2025	2025	NUM
aji-173	148	6	;	;	PUNCT
aji-173	148	7	article	article	NOUN
aji-173	148	8	no.aji.141940	no.aji.141940	VERB
aji-173	148	9	224	224	NUM
aji-173	148	10	fig	fig	NOUN
aji-173	148	11	.	.	PUNCT
aji-173	149	1	1	1	X
aji-173	149	2	.	.	PUNCT
aji-173	150	1	the	the	DET
aji-173	150	2	electrophoretic	electrophoretic	ADJ
aji-173	150	3	profile	profile	NOUN
aji-173	150	4	of	of	ADP
aji-173	150	5	our	our	PRON
aji-173	150	6	patient	patient	NOUN
aji-173	150	7	's	's	PART
aji-173	150	8	serum	serum	NOUN
aji-173	150	9	proteins	protein	NOUN
aji-173	150	10	,	,	PUNCT
aji-173	150	11	performed	perform	VERB
aji-173	150	12	on	on	ADP
aji-173	150	13	agarose	agarose	NOUN
aji-173	150	14	gel	gel	NOUN
aji-173	150	15	,	,	PUNCT
aji-173	150	16	shows	show	VERB
aji-173	150	17	a	a	DET
aji-173	150	18	monoclonal	monoclonal	NOUN
aji-173	150	19	band	band	NOUN
aji-173	150	20	located	locate	VERB
aji-173	150	21	in	in	ADP
aji-173	150	22	the	the	DET
aji-173	150	23	gamma	gamma	NOUN
aji-173	150	24	globulin	globulin	NOUN
aji-173	150	25	zone	zone	NOUN
aji-173	150	26	at	at	ADP
aji-173	150	27	position	position	NOUN
aji-173	150	28	21	21	NUM
aji-173	150	29	.	.	PUNCT
aji-173	151	1	this	this	DET
aji-173	151	2	observation	observation	NOUN
aji-173	151	3	confirms	confirm	VERB
aji-173	151	4	the	the	DET
aji-173	151	5	presence	presence	NOUN
aji-173	151	6	of	of	ADP
aji-173	151	7	a	a	DET
aji-173	151	8	monoclonal	monoclonal	NOUN
aji-173	151	9	immunoglobulin	immunoglobulin	NOUN
aji-173	151	10	,	,	PUNCT
aji-173	151	11	attesting	attest	VERB
aji-173	151	12	to	to	ADP
aji-173	151	13	the	the	DET
aji-173	151	14	clonal	clonal	ADJ
aji-173	151	15	nature	nature	NOUN
aji-173	151	16	of	of	ADP
aji-173	151	17	the	the	DET
aji-173	151	18	detected	detect	VERB
aji-173	151	19	protein	protein	NOUN
aji-173	151	20	fig	fig	NOUN
aji-173	151	21	.	.	PUNCT
aji-173	152	1	2	2	X
aji-173	152	2	.	.	X
aji-173	152	3	the	the	DET
aji-173	152	4	electrophoretic	electrophoretic	ADJ
aji-173	152	5	pattern	pattern	NOUN
aji-173	152	6	of	of	ADP
aji-173	152	7	the	the	DET
aji-173	152	8	protein	protein	NOUN
aji-173	152	9	profile	profile	NOUN
aji-173	152	10	at	at	ADP
aji-173	152	11	position	position	NOUN
aji-173	152	12	21	21	NUM
aji-173	152	13	shows	show	VERB
aji-173	152	14	a	a	DET
aji-173	152	15	monoclonal	monoclonal	NOUN
aji-173	152	16	peak	peak	NOUN
aji-173	152	17	in	in	ADP
aji-173	152	18	the	the	DET
aji-173	152	19	gamma	gamma	NOUN
aji-173	152	20	globulin	globulin	NOUN
aji-173	152	21	zone	zone	NOUN
aji-173	152	22	,	,	PUNCT
aji-173	152	23	with	with	ADP
aji-173	152	24	an	an	DET
aji-173	152	25	estimated	estimate	VERB
aji-173	152	26	concentration	concentration	NOUN
aji-173	152	27	of	of	ADP
aji-173	152	28	40	40	NUM
aji-173	152	29	g	g	NOUN
aji-173	152	30	/	/	SYM
aji-173	152	31	l	l	NOUN
aji-173	152	32	,	,	PUNCT
aji-173	152	33	accompanied	accompany	VERB
aji-173	152	34	by	by	ADP
aji-173	152	35	a	a	DET
aji-173	152	36	decrease	decrease	NOUN
aji-173	152	37	(	(	PUNCT
aji-173	152	38	suppression	suppression	NOUN
aji-173	152	39	)	)	PUNCT
aji-173	152	40	in	in	ADP
aji-173	152	41	other	other	ADJ
aji-173	152	42	classes	class	NOUN
aji-173	152	43	of	of	ADP
aji-173	152	44	polyclonal	polyclonal	ADJ
aji-173	152	45	immunoglobulins	immunoglobulin	NOUN
aji-173	152	46	meriche	meriche	PROPN
aji-173	152	47	et	et	PROPN
aji-173	152	48	al	al	PROPN
aji-173	152	49	.	.	PROPN
aji-173	152	50	;	;	PUNCT
aji-173	153	1	asian	asian	PROPN
aji-173	153	2	j.	j.	PROPN
aji-173	153	3	immunol	immunol	PROPN
aji-173	153	4	.	.	PROPN
aji-173	153	5	,	,	PUNCT
aji-173	153	6	vol	vol	NOUN
aji-173	153	7	.	.	PROPN
aji-173	153	8	8	8	NUM
aji-173	153	9	,	,	PUNCT
aji-173	153	10	no	no	INTJ
aji-173	153	11	.	.	NOUN
aji-173	153	12	1	1	NUM
aji-173	153	13	,	,	PUNCT
aji-173	153	14	pp	pp	ADJ
aji-173	153	15	.	.	PUNCT
aji-173	154	1	222	222	NUM
aji-173	154	2	-	-	SYM
aji-173	154	3	229	229	NUM
aji-173	154	4	,	,	PUNCT
aji-173	154	5	2025	2025	NUM
aji-173	154	6	;	;	PUNCT
aji-173	154	7	article	article	NOUN
aji-173	154	8	no.aji.141940	no.aji.141940	VERB
aji-173	154	9	225	225	NUM
aji-173	154	10	clinically	clinically	ADV
aji-173	154	11	,	,	PUNCT
aji-173	154	12	the	the	DET
aji-173	154	13	presence	presence	NOUN
aji-173	154	14	of	of	ADP
aji-173	154	15	anemia	anemia	NOUN
aji-173	154	16	,	,	PUNCT
aji-173	154	17	renal	renal	ADJ
aji-173	154	18	failure	failure	NOUN
aji-173	154	19	,	,	PUNCT
aji-173	154	20	hypercalcemia	hypercalcemia	NOUN
aji-173	154	21	,	,	PUNCT
aji-173	154	22	and	and	CCONJ
aji-173	154	23	osteolytic	osteolytic	ADJ
aji-173	154	24	bone	bone	NOUN
aji-173	154	25	lesions	lesion	NOUN
aji-173	154	26	meets	meet	VERB
aji-173	154	27	the	the	DET
aji-173	154	28	crab	crab	NOUN
aji-173	154	29	criteria	criterion	NOUN
aji-173	154	30	of	of	ADP
aji-173	154	31	the	the	DET
aji-173	154	32	imwg	imwg	NOUN
aji-173	154	33	(	(	PUNCT
aji-173	154	34	international	international	ADJ
aji-173	154	35	myeloma	myeloma	PROPN
aji-173	154	36	working	working	NOUN
aji-173	154	37	group	group	NOUN
aji-173	154	38	)	)	PUNCT
aji-173	154	39	,	,	PUNCT
aji-173	154	40	justifying	justify	VERB
aji-173	154	41	a	a	DET
aji-173	154	42	diagnosis	diagnosis	NOUN
aji-173	154	43	of	of	ADP
aji-173	154	44	myeloma	myeloma	NOUN
aji-173	154	45	in	in	ADP
aji-173	154	46	the	the	DET
aji-173	154	47	active	active	ADJ
aji-173	154	48	phase	phase	NOUN
aji-173	154	49	.	.	PUNCT
aji-173	155	1	the	the	DET
aji-173	155	2	iss	iss	PROPN
aji-173	155	3	(	(	PUNCT
aji-173	155	4	international	international	ADJ
aji-173	155	5	staging	staging	NOUN
aji-173	155	6	system	system	NOUN
aji-173	155	7	)	)	PUNCT
aji-173	155	8	classification	classification	NOUN
aji-173	155	9	of	of	ADP
aji-173	155	10	stage	stage	NOUN
aji-173	155	11	ii	ii	PROPN
aji-173	155	12	reflects	reflect	VERB
aji-173	155	13	a	a	DET
aji-173	155	14	high	high	ADJ
aji-173	155	15	tumor	tumor	NOUN
aji-173	155	16	burden	burden	NOUN
aji-173	155	17	and	and	CCONJ
aji-173	155	18	a	a	DET
aji-173	155	19	guarded	guard	VERB
aji-173	155	20	prognosis	prognosis	NOUN
aji-173	155	21	.	.	PUNCT
aji-173	156	1	this	this	DET
aji-173	156	2	complex	complex	ADJ
aji-173	156	3	diagnosis	diagnosis	NOUN
aji-173	156	4	requires	require	VERB
aji-173	156	5	appropriate	appropriate	ADJ
aji-173	156	6	management	management	NOUN
aji-173	156	7	,	,	PUNCT
aji-173	156	8	which	which	PRON
aji-173	156	9	is	be	AUX
aji-173	156	10	even	even	ADV
aji-173	156	11	more	more	ADV
aji-173	156	12	delicate	delicate	ADJ
aji-173	156	13	in	in	ADP
aji-173	156	14	the	the	DET
aji-173	156	15	case	case	NOUN
aji-173	156	16	of	of	ADP
aji-173	156	17	pregnancy	pregnancy	NOUN
aji-173	156	18	.	.	PUNCT
aji-173	157	1	2.4	2.4	NUM
aji-173	157	2	management	management	NOUN
aji-173	157	3	and	and	CCONJ
aji-173	157	4	follow	follow	VERB
aji-173	157	5	-	-	PUNCT
aji-173	157	6	up	up	NOUN
aji-173	157	7	due	due	ADP
aji-173	157	8	to	to	ADP
aji-173	157	9	the	the	DET
aji-173	157	10	high	high	ADJ
aji-173	157	11	teratogenic	teratogenic	ADJ
aji-173	157	12	risk	risk	NOUN
aji-173	157	13	,	,	PUNCT
aji-173	157	14	chemotherapy	chemotherapy	NOUN
aji-173	157	15	is	be	AUX
aji-173	157	16	postponed	postpone	VERB
aji-173	157	17	during	during	ADP
aji-173	157	18	pregnancy	pregnancy	NOUN
aji-173	157	19	,	,	PUNCT
aji-173	157	20	especially	especially	ADV
aji-173	157	21	during	during	ADP
aji-173	157	22	the	the	DET
aji-173	157	23	first	first	ADJ
aji-173	157	24	and	and	CCONJ
aji-173	157	25	second	second	ADJ
aji-173	157	26	trimesters	trimester	NOUN
aji-173	157	27	,	,	PUNCT
aji-173	157	28	with	with	ADP
aji-173	157	29	regular	regular	ADJ
aji-173	157	30	monthly	monthly	ADJ
aji-173	157	31	clinical	clinical	ADJ
aji-173	157	32	and	and	CCONJ
aji-173	157	33	biological	biological	ADJ
aji-173	157	34	monitoring	monitoring	NOUN
aji-173	157	35	based	base	VERB
aji-173	157	36	on	on	ADP
aji-173	157	37	blood	blood	NOUN
aji-173	157	38	counts	count	NOUN
aji-173	157	39	,	,	PUNCT
aji-173	157	40	renal	renal	ADJ
aji-173	157	41	function	function	NOUN
aji-173	157	42	tests	test	NOUN
aji-173	157	43	,	,	PUNCT
aji-173	157	44	calcemia	calcemia	NOUN
aji-173	157	45	measurements	measurement	NOUN
aji-173	157	46	,	,	PUNCT
aji-173	157	47	protein	protein	NOUN
aji-173	157	48	electrophoresis	electrophoresis	NOUN
aji-173	157	49	(	(	PUNCT
aji-173	157	50	fig	fig	NOUN
aji-173	157	51	.	.	PUNCT
aji-173	158	1	4a	4a	NOUN
aji-173	158	2	/	/	SYM
aji-173	158	3	b	b	NOUN
aji-173	158	4	)	)	PUNCT
aji-173	158	5	,	,	PUNCT
aji-173	158	6	and	and	CCONJ
aji-173	158	7	weekly	weekly	ADJ
aji-173	158	8	ultrasounds	ultrasound	NOUN
aji-173	158	9	to	to	PART
aji-173	158	10	ensure	ensure	VERB
aji-173	158	11	maternal	maternal	ADJ
aji-173	158	12	-	-	PUNCT
aji-173	158	13	fetal	fetal	ADJ
aji-173	158	14	stability	stability	NOUN
aji-173	158	15	and	and	CCONJ
aji-173	158	16	a	a	DET
aji-173	158	17	complication	complication	NOUN
aji-173	158	18	-	-	PUNCT
aji-173	158	19	free	free	ADJ
aji-173	158	20	pregnancy	pregnancy	NOUN
aji-173	158	21	.	.	PUNCT
aji-173	159	1	after	after	ADP
aji-173	159	2	delivery	delivery	NOUN
aji-173	159	3	,	,	PUNCT
aji-173	159	4	treatment	treatment	NOUN
aji-173	159	5	with	with	ADP
aji-173	159	6	the	the	DET
aji-173	159	7	vtd	vtd	ADJ
aji-173	159	8	protocol	protocol	NOUN
aji-173	159	9	(	(	PUNCT
aji-173	159	10	treatment	treatment	NOUN
aji-173	159	11	using	use	VERB
aji-173	159	12	bortezomib	bortezomib	NOUN
aji-173	159	13	(	(	PUNCT
aji-173	159	14	velcade	velcade	PROPN
aji-173	159	15	)	)	PUNCT
aji-173	159	16	,	,	PUNCT
aji-173	159	17	lenalidomide	lenalidomide	VERB
aji-173	159	18	(	(	PUNCT
aji-173	159	19	revlimid	revlimid	NOUN
aji-173	159	20	)	)	PUNCT
aji-173	159	21	,	,	PUNCT
aji-173	159	22	and	and	CCONJ
aji-173	159	23	dexamethasone	dexamethasone	NOUN
aji-173	159	24	)	)	PUNCT
aji-173	159	25	,	,	PUNCT
aji-173	159	26	which	which	PRON
aji-173	159	27	is	be	AUX
aji-173	159	28	effective	effective	ADJ
aji-173	159	29	and	and	CCONJ
aji-173	159	30	well	well	ADV
aji-173	159	31	tolerated	tolerate	VERB
aji-173	159	32	,	,	PUNCT
aji-173	159	33	leading	lead	VERB
aji-173	159	34	to	to	ADP
aji-173	159	35	complete	complete	ADJ
aji-173	159	36	remission	remission	NOUN
aji-173	159	37	.	.	PUNCT
aji-173	160	1	this	this	DET
aji-173	160	2	success	success	NOUN
aji-173	160	3	highlights	highlight	VERB
aji-173	160	4	the	the	DET
aji-173	160	5	importance	importance	NOUN
aji-173	160	6	of	of	ADP
aji-173	160	7	appropriate	appropriate	ADJ
aji-173	160	8	and	and	CCONJ
aji-173	160	9	deferred	deferred	ADJ
aji-173	160	10	treatment	treatment	NOUN
aji-173	160	11	,	,	PUNCT
aji-173	160	12	combined	combine	VERB
aji-173	160	13	with	with	ADP
aji-173	160	14	multidisciplinary	multidisciplinary	ADJ
aji-173	160	15	post	post	ADJ
aji-173	160	16	-	-	ADJ
aji-173	160	17	treatment	treatment	ADJ
aji-173	160	18	follow	follow	NOUN
aji-173	160	19	-	-	PUNCT
aji-173	160	20	up	up	NOUN
aji-173	160	21	(	(	PUNCT
aji-173	160	22	hematologist	hematologist	ADJ
aji-173	160	23	,	,	PUNCT
aji-173	160	24	gynecologist	gynecologist	NOUN
aji-173	160	25	,	,	PUNCT
aji-173	160	26	nephrologist	nephrologist	NOUN
aji-173	160	27	,	,	PUNCT
aji-173	160	28	immunologist	immunologist	NOUN
aji-173	160	29	)	)	PUNCT
aji-173	160	30	to	to	PART
aji-173	160	31	detect	detect	VERB
aji-173	160	32	any	any	DET
aji-173	160	33	relapses	relapse	NOUN
aji-173	160	34	or	or	CCONJ
aji-173	160	35	side	side	NOUN
aji-173	160	36	effects	effect	NOUN
aji-173	160	37	and	and	CCONJ
aji-173	160	38	ensure	ensure	VERB
aji-173	160	39	optimal	optimal	ADJ
aji-173	160	40	long	long	ADJ
aji-173	160	41	-	-	PUNCT
aji-173	160	42	term	term	NOUN
aji-173	160	43	care	care	NOUN
aji-173	160	44	.	.	PUNCT
aji-173	161	1	fig	fig	NOUN
aji-173	161	2	.	.	PUNCT
aji-173	162	1	3	3	X
aji-173	162	2	.	.	X
aji-173	162	3	immunofixation	immunofixation	NOUN
aji-173	162	4	results	result	NOUN
aji-173	162	5	from	from	ADP
aji-173	162	6	our	our	PRON
aji-173	162	7	case	case	NOUN
aji-173	162	8	show	show	VERB
aji-173	162	9	that	that	SCONJ
aji-173	162	10	the	the	DET
aji-173	162	11	monoclonal	monoclonal	NOUN
aji-173	162	12	peak	peak	NOUN
aji-173	162	13	corresponds	correspond	VERB
aji-173	162	14	to	to	ADP
aji-173	162	15	an	an	DET
aji-173	162	16	igg	igg	PROPN
aji-173	162	17	kappa	kappa	PROPN
aji-173	162	18	immunoglobulin	immunoglobulin	PROPN
aji-173	162	19	,	,	PUNCT
aji-173	162	20	with	with	ADP
aji-173	162	21	a	a	DET
aji-173	162	22	decrease	decrease	NOUN
aji-173	162	23	in	in	ADP
aji-173	162	24	other	other	ADJ
aji-173	162	25	types	type	NOUN
aji-173	162	26	of	of	ADP
aji-173	162	27	polyclonal	polyclonal	ADJ
aji-173	162	28	immunoglobulins	immunoglobulin	NOUN
aji-173	162	29	4	4	NUM
aji-173	162	30	a.	a.	NOUN
aji-173	162	31	meriche	meriche	NOUN
aji-173	162	32	et	et	PROPN
aji-173	162	33	al	al	PROPN
aji-173	162	34	.	.	PROPN
aji-173	162	35	;	;	PUNCT
aji-173	163	1	asian	asian	PROPN
aji-173	163	2	j.	j.	PROPN
aji-173	163	3	immunol	immunol	PROPN
aji-173	163	4	.	.	PROPN
aji-173	163	5	,	,	PUNCT
aji-173	163	6	vol	vol	NOUN
aji-173	163	7	.	.	PROPN
aji-173	163	8	8	8	NUM
aji-173	163	9	,	,	PUNCT
aji-173	163	10	no	no	INTJ
aji-173	163	11	.	.	NOUN
aji-173	163	12	1	1	NUM
aji-173	163	13	,	,	PUNCT
aji-173	163	14	pp	pp	ADJ
aji-173	163	15	.	.	PUNCT
aji-173	164	1	222	222	NUM
aji-173	164	2	-	-	SYM
aji-173	164	3	229	229	NUM
aji-173	164	4	,	,	PUNCT
aji-173	164	5	2025	2025	NUM
aji-173	164	6	;	;	PUNCT
aji-173	164	7	article	article	NOUN
aji-173	164	8	no.aji.141940	no.aji.141940	NOUN
aji-173	164	9	226	226	NUM
aji-173	164	10	4b	4b	X
aji-173	164	11	.	.	PUNCT
aji-173	165	1	fig	fig	NOUN
aji-173	165	2	.	.	PUNCT
aji-173	166	1	4	4	NUM
aji-173	166	2	a	a	DET
aji-173	166	3	/	/	SYM
aji-173	166	4	b.	b.	NOUN
aji-173	166	5	regression	regression	NOUN
aji-173	166	6	of	of	ADP
aji-173	166	7	the	the	DET
aji-173	166	8	monoclonal	monoclonal	NOUN
aji-173	166	9	peak	peak	NOUN
aji-173	166	10	after	after	ADP
aji-173	166	11	postpartum	postpartum	NOUN
aji-173	166	12	treatment	treatment	NOUN
aji-173	166	13	with	with	ADP
aji-173	166	14	the	the	DET
aji-173	166	15	vtd	vtd	ADJ
aji-173	166	16	protocol	protocol	NOUN
aji-173	166	17	in	in	ADP
aji-173	166	18	our	our	PRON
aji-173	166	19	patient	patient	NOUN
aji-173	166	20	with	with	ADP
aji-173	166	21	gestational	gestational	ADJ
aji-173	166	22	myeloma	myeloma	NOUN
aji-173	166	23	3	3	NUM
aji-173	166	24	.	.	PUNCT
aji-173	166	25	discussion	discussion	NOUN
aji-173	166	26	multiple	multiple	ADJ
aji-173	166	27	myeloma	myeloma	NOUN
aji-173	166	28	(	(	PUNCT
aji-173	166	29	mm	mm	NOUN
aji-173	166	30	)	)	PUNCT
aji-173	166	31	is	be	AUX
aji-173	166	32	a	a	DET
aji-173	166	33	malignant	malignant	ADJ
aji-173	166	34	blood	blood	NOUN
aji-173	166	35	disorder	disorder	NOUN
aji-173	166	36	characterized	characterize	VERB
aji-173	166	37	by	by	ADP
aji-173	166	38	clonal	clonal	ADJ
aji-173	166	39	proliferation	proliferation	NOUN
aji-173	166	40	of	of	ADP
aji-173	166	41	plasma	plasma	NOUN
aji-173	166	42	cells	cell	NOUN
aji-173	166	43	in	in	ADP
aji-173	166	44	the	the	DET
aji-173	166	45	bone	bone	NOUN
aji-173	166	46	marrow	marrow	NOUN
aji-173	166	47	,	,	PUNCT
aji-173	166	48	associated	associate	VERB
aji-173	166	49	with	with	ADP
aji-173	166	50	excessive	excessive	ADJ
aji-173	166	51	monoclonal	monoclonal	NOUN
aji-173	166	52	production	production	NOUN
aji-173	166	53	of	of	ADP
aji-173	166	54	immunoglobulins	immunoglobulin	NOUN
aji-173	166	55	(	(	PUNCT
aji-173	166	56	kyle	kyle	PROPN
aji-173	166	57	&	&	CCONJ
aji-173	166	58	rajkumar	rajkumar	PROPN
aji-173	166	59	,	,	PUNCT
aji-173	166	60	2004	2004	NUM
aji-173	166	61	)	)	PUNCT
aji-173	166	62	.	.	PUNCT
aji-173	167	1	the	the	DET
aji-173	167	2	igg	igg	PROPN
aji-173	167	3	kappa	kappa	PROPN
aji-173	167	4	form	form	PROPN
aji-173	167	5	identified	identify	VERB
aji-173	167	6	in	in	ADP
aji-173	167	7	our	our	PRON
aji-173	167	8	patient	patient	NOUN
aji-173	167	9	corresponds	correspond	NOUN
aji-173	167	10	to	to	ADP
aji-173	167	11	the	the	DET
aji-173	167	12	most	most	ADV
aji-173	167	13	frequently	frequently	ADV
aji-173	167	14	observed	observe	VERB
aji-173	167	15	type	type	NOUN
aji-173	167	16	in	in	ADP
aji-173	167	17	the	the	DET
aji-173	167	18	general	general	ADJ
aji-173	167	19	population	population	NOUN
aji-173	167	20	,	,	PUNCT
aji-173	167	21	which	which	PRON
aji-173	167	22	is	be	AUX
aji-173	167	23	consistent	consistent	ADJ
aji-173	167	24	with	with	ADP
aji-173	167	25	the	the	DET
aji-173	167	26	epidemiological	epidemiological	ADJ
aji-173	167	27	and	and	CCONJ
aji-173	167	28	biological	biological	ADJ
aji-173	167	29	data	datum	NOUN
aji-173	167	30	reported	report	VERB
aji-173	167	31	by	by	ADP
aji-173	167	32	palumbo	palumbo	PROPN
aji-173	167	33	and	and	CCONJ
aji-173	167	34	anderson	anderson	PROPN
aji-173	167	35	(	(	PUNCT
aji-173	167	36	2011	2011	NUM
aji-173	167	37	)	)	PUNCT
aji-173	167	38	and	and	CCONJ
aji-173	167	39	corroborated	corroborate	VERB
aji-173	167	40	by	by	ADP
aji-173	167	41	kyle	kyle	NOUN
aji-173	167	42	and	and	CCONJ
aji-173	167	43	rajkumar	rajkumar	PROPN
aji-173	167	44	(	(	PUNCT
aji-173	167	45	2004	2004	NUM
aji-173	167	46	)	)	PUNCT
aji-173	167	47	;	;	PUNCT
aji-173	167	48	palumbo	palumbo	PROPN
aji-173	167	49	&	&	CCONJ
aji-173	167	50	anderson	anderson	PROPN
aji-173	167	51	,	,	PUNCT
aji-173	167	52	2011	2011	NUM
aji-173	167	53	;	;	PUNCT
aji-173	167	54	johns	johns	PROPN
aji-173	167	55	hopkins	hopkins	PROPN
aji-173	167	56	university	university	PROPN
aji-173	167	57	school	school	NOUN
aji-173	167	58	of	of	ADP
aji-173	167	59	medicine	medicine	NOUN
aji-173	167	60	,	,	PUNCT
aji-173	167	61	2024	2024	NUM
aji-173	167	62	)	)	PUNCT
aji-173	167	63	.	.	PUNCT
aji-173	168	1	immunoparesis	immunoparesis	PROPN
aji-173	168	2	,	,	PUNCT
aji-173	168	3	resulting	result	VERB
aji-173	168	4	from	from	ADP
aji-173	168	5	the	the	DET
aji-173	168	6	suppression	suppression	NOUN
aji-173	168	7	of	of	ADP
aji-173	168	8	polyclonal	polyclonal	ADJ
aji-173	168	9	immunoglobulins	immunoglobulin	NOUN
aji-173	168	10	,	,	PUNCT
aji-173	168	11	is	be	AUX
aji-173	168	12	a	a	DET
aji-173	168	13	mechanism	mechanism	NOUN
aji-173	168	14	well	well	ADV
aji-173	168	15	described	describe	VERB
aji-173	168	16	in	in	ADP
aji-173	168	17	the	the	DET
aji-173	168	18	literature	literature	NOUN
aji-173	168	19	,	,	PUNCT
aji-173	168	20	promoting	promote	VERB
aji-173	168	21	significant	significant	ADJ
aji-173	168	22	immunosuppression	immunosuppression	NOUN
aji-173	168	23	and	and	CCONJ
aji-173	168	24	vulnerability	vulnerability	NOUN
aji-173	168	25	to	to	ADP
aji-173	168	26	opportunistic	opportunistic	ADJ
aji-173	168	27	infections	infection	NOUN
aji-173	168	28	(	(	PUNCT
aji-173	168	29	rajkumar	rajkumar	PROPN
aji-173	168	30	,	,	PUNCT
aji-173	168	31	1999	1999	NUM
aji-173	168	32	;	;	PUNCT
aji-173	168	33	la	la	PROPN
aji-173	168	34	revue	revue	PROPN
aji-173	168	35	du	du	PROPN
aji-173	168	36	praticien	praticien	PROPN
aji-173	168	37	,	,	PUNCT
aji-173	168	38	2023	2023	NUM
aji-173	168	39	)	)	PUNCT
aji-173	168	40	.	.	PUNCT
aji-173	169	1	this	this	DET
aji-173	169	2	immunosuppression	immunosuppression	NOUN
aji-173	169	3	was	be	AUX
aji-173	169	4	highlighted	highlight	VERB
aji-173	169	5	by	by	ADP
aji-173	169	6	rajkumar	rajkumar	PROPN
aji-173	169	7	(	(	PUNCT
aji-173	169	8	2011	2011	NUM
aji-173	169	9	)	)	PUNCT
aji-173	169	10	,	,	PUNCT
aji-173	169	11	who	who	PRON
aji-173	169	12	emphasized	emphasize	VERB
aji-173	169	13	its	its	PRON
aji-173	169	14	prognostic	prognostic	ADJ
aji-173	169	15	effect	effect	NOUN
aji-173	169	16	and	and	CCONJ
aji-173	169	17	therapeutic	therapeutic	ADJ
aji-173	169	18	implications	implication	NOUN
aji-173	169	19	,	,	PUNCT
aji-173	169	20	in	in	ADP
aji-173	169	21	line	line	NOUN
aji-173	169	22	with	with	ADP
aji-173	169	23	the	the	DET
aji-173	169	24	clinical	clinical	ADJ
aji-173	169	25	observations	observation	NOUN
aji-173	169	26	made	make	VERB
aji-173	169	27	in	in	ADP
aji-173	169	28	our	our	PRON
aji-173	169	29	patient	patient	NOUN
aji-173	169	30	.	.	PUNCT
aji-173	170	1	epidemiologically	epidemiologically	PROPN
aji-173	170	2	,	,	PUNCT
aji-173	170	3	mm	mm	PROPN
aji-173	170	4	primarily	primarily	ADV
aji-173	170	5	affects	affect	VERB
aji-173	170	6	older	old	ADJ
aji-173	170	7	populations	population	NOUN
aji-173	170	8	,	,	PUNCT
aji-173	170	9	with	with	ADP
aji-173	170	10	less	less	ADJ
aji-173	170	11	than	than	ADP
aji-173	170	12	3	3	NUM
aji-173	170	13	%	%	NOUN
aji-173	170	14	of	of	ADP
aji-173	170	15	cases	case	NOUN
aji-173	170	16	diagnosed	diagnose	VERB
aji-173	170	17	before	before	ADP
aji-173	170	18	the	the	DET
aji-173	170	19	age	age	NOUN
aji-173	170	20	of	of	ADP
aji-173	170	21	40	40	NUM
aji-173	170	22	,	,	PUNCT
aji-173	170	23	which	which	PRON
aji-173	170	24	is	be	AUX
aji-173	170	25	linked	link	VERB
aji-173	170	26	to	to	ADP
aji-173	170	27	female	female	ADJ
aji-173	170	28	fertility	fertility	NOUN
aji-173	170	29	(	(	PUNCT
aji-173	170	30	steinbach	steinbach	NOUN
aji-173	170	31	,	,	PUNCT
aji-173	170	32	2024	2024	NUM
aji-173	170	33	;	;	PUNCT
aji-173	170	34	abdellah	abdellah	PROPN
aji-173	170	35	et	et	PROPN
aji-173	170	36	al	al	PROPN
aji-173	170	37	.	.	PROPN
aji-173	170	38	,	,	PUNCT
aji-173	170	39	2020	2020	NUM
aji-173	170	40	)	)	PUNCT
aji-173	170	41	.	.	PUNCT
aji-173	171	1	our	our	PRON
aji-173	171	2	observation	observation	NOUN
aji-173	171	3	is	be	AUX
aji-173	171	4	thus	thus	ADV
aji-173	171	5	consistent	consistent	ADJ
aji-173	171	6	with	with	ADP
aji-173	171	7	the	the	DET
aji-173	171	8	rare	rare	ADJ
aji-173	171	9	descriptions	description	NOUN
aji-173	171	10	of	of	ADP
aji-173	171	11	mm	mm	PROPN
aji-173	171	12	in	in	ADP
aji-173	171	13	the	the	DET
aji-173	171	14	context	context	NOUN
aji-173	171	15	of	of	ADP
aji-173	171	16	pregnancy	pregnancy	NOUN
aji-173	171	17	,	,	PUNCT
aji-173	171	18	as	as	SCONJ
aji-173	171	19	confirmed	confirm	VERB
aji-173	171	20	by	by	ADP
aji-173	171	21	the	the	DET
aji-173	171	22	reviews	review	NOUN
aji-173	171	23	by	by	ADP
aji-173	171	24	kumar	kumar	PROPN
aji-173	171	25	et	et	PROPN
aji-173	171	26	al	al	PROPN
aji-173	171	27	.	.	PROPN
aji-173	172	1	(	(	PUNCT
aji-173	172	2	2003	2003	NUM
aji-173	172	3	)	)	PUNCT
aji-173	172	4	and	and	CCONJ
aji-173	172	5	lee	lee	PROPN
aji-173	172	6	et	et	PROPN
aji-173	172	7	al	al	PROPN
aji-173	172	8	.	.	PROPN
aji-173	173	1	(	(	PUNCT
aji-173	173	2	2016	2016	NUM
aji-173	173	3	)	)	PUNCT
aji-173	173	4	,	,	PUNCT
aji-173	173	5	which	which	PRON
aji-173	173	6	emphasize	emphasize	VERB
aji-173	173	7	the	the	DET
aji-173	173	8	rarity	rarity	NOUN
aji-173	173	9	and	and	CCONJ
aji-173	173	10	complexity	complexity	NOUN
aji-173	173	11	of	of	ADP
aji-173	173	12	management	management	NOUN
aji-173	173	13	in	in	ADP
aji-173	173	14	this	this	DET
aji-173	173	15	specific	specific	ADJ
aji-173	173	16	situation	situation	NOUN
aji-173	173	17	(	(	PUNCT
aji-173	173	18	szydełko	szydełko	NOUN
aji-173	173	19	,	,	PUNCT
aji-173	173	20	2019	2019	NUM
aji-173	173	21	;	;	PUNCT
aji-173	173	22	pajor	pajor	NOUN
aji-173	173	23	,	,	PUNCT
aji-173	173	24	1991	1991	NUM
aji-173	173	25	)	)	PUNCT
aji-173	173	26	.	.	PUNCT
aji-173	174	1	the	the	DET
aji-173	174	2	clinical	clinical	ADJ
aji-173	174	3	presentation	presentation	NOUN
aji-173	174	4	of	of	ADP
aji-173	174	5	mm	mm	PROPN
aji-173	174	6	during	during	ADP
aji-173	174	7	pregnancy	pregnancy	NOUN
aji-173	174	8	is	be	AUX
aji-173	174	9	often	often	ADV
aji-173	174	10	atypical	atypical	ADJ
aji-173	174	11	.	.	PUNCT
aji-173	175	1	anemia	anemia	NOUN
aji-173	175	2	,	,	PUNCT
aji-173	175	3	which	which	PRON
aji-173	175	4	is	be	AUX
aji-173	175	5	very	very	ADV
aji-173	175	6	common	common	ADJ
aji-173	175	7	during	during	ADP
aji-173	175	8	pregnancy	pregnancy	NOUN
aji-173	175	9	,	,	PUNCT
aji-173	175	10	particularly	particularly	ADV
aji-173	175	11	due	due	ADJ
aji-173	175	12	to	to	ADP
aji-173	175	13	nutritional	nutritional	ADJ
aji-173	175	14	deficiencies	deficiency	NOUN
aji-173	175	15	,	,	PUNCT
aji-173	175	16	is	be	AUX
aji-173	175	17	a	a	DET
aji-173	175	18	common	common	ADJ
aji-173	175	19	factor	factor	NOUN
aji-173	175	20	that	that	PRON
aji-173	175	21	can	can	AUX
aji-173	175	22	lead	lead	VERB
aji-173	175	23	to	to	ADP
aji-173	175	24	delayed	delay	VERB
aji-173	175	25	diagnosis	diagnosis	NOUN
aji-173	175	26	of	of	ADP
aji-173	175	27	serious	serious	ADJ
aji-173	175	28	conditions	condition	NOUN
aji-173	175	29	such	such	ADJ
aji-173	175	30	as	as	ADP
aji-173	175	31	mm	mm	PROPN
aji-173	175	32	.	.	PUNCT
aji-173	176	1	this	this	PRON
aji-173	176	2	is	be	AUX
aji-173	176	3	clearly	clearly	ADV
aji-173	176	4	illustrated	illustrate	VERB
aji-173	176	5	in	in	ADP
aji-173	176	6	our	our	PRON
aji-173	176	7	observation	observation	NOUN
aji-173	176	8	by	by	ADP
aji-173	176	9	anemia	anemia	NOUN
aji-173	176	10	that	that	PRON
aji-173	176	11	is	be	AUX
aji-173	176	12	refractory	refractory	NOUN
aji-173	176	13	to	to	PART
aji-173	176	14	iron	iron	VERB
aji-173	176	15	treatment	treatment	NOUN
aji-173	176	16	,	,	PUNCT
aji-173	176	17	a	a	DET
aji-173	176	18	situation	situation	NOUN
aji-173	176	19	also	also	ADV
aji-173	176	20	highlighted	highlight	VERB
aji-173	176	21	by	by	ADP
aji-173	176	22	smith	smith	PROPN
aji-173	176	23	et	et	PROPN
aji-173	176	24	al	al	PROPN
aji-173	176	25	.	.	PROPN
aji-173	177	1	(	(	PUNCT
aji-173	177	2	2012	2012	NUM
aji-173	177	3	)	)	PUNCT
aji-173	177	4	,	,	PUNCT
aji-173	177	5	who	who	PRON
aji-173	177	6	recommend	recommend	VERB
aji-173	177	7	thorough	thorough	ADJ
aji-173	177	8	investigation	investigation	NOUN
aji-173	177	9	of	of	ADP
aji-173	177	10	persistent	persistent	ADJ
aji-173	177	11	unexplained	unexplained	ADJ
aji-173	177	12	anemia	anemia	NOUN
aji-173	177	13	in	in	ADP
aji-173	177	14	pregnant	pregnant	ADJ
aji-173	177	15	women	woman	NOUN
aji-173	177	16	(	(	PUNCT
aji-173	177	17	mor	mor	PROPN
aji-173	177	18	&	&	CCONJ
aji-173	177	19	cardenas	cardenas	PROPN
aji-173	177	20	,	,	PUNCT
aji-173	177	21	2010	2010	NUM
aji-173	177	22	)	)	PUNCT
aji-173	177	23	.	.	PUNCT
aji-173	178	1	serum	serum	NOUN
aji-173	178	2	protein	protein	NOUN
aji-173	178	3	electrophoresis	electrophoresis	NOUN
aji-173	178	4	and	and	CCONJ
aji-173	178	5	free	free	ADJ
aji-173	178	6	light	light	NOUN
aji-173	178	7	chain	chain	NOUN
aji-173	178	8	assay	assay	VERB
aji-173	178	9	,	,	PUNCT
aji-173	178	10	as	as	SCONJ
aji-173	178	11	indicated	indicate	VERB
aji-173	178	12	in	in	ADP
aji-173	178	13	our	our	PRON
aji-173	178	14	diagnosis	diagnosis	NOUN
aji-173	178	15	,	,	PUNCT
aji-173	178	16	are	be	AUX
aji-173	178	17	now	now	ADV
aji-173	178	18	considered	consider	VERB
aji-173	178	19	key	key	ADJ
aji-173	178	20	tests	test	NOUN
aji-173	178	21	for	for	ADP
aji-173	178	22	the	the	DET
aji-173	178	23	early	early	ADJ
aji-173	178	24	detection	detection	NOUN
aji-173	178	25	of	of	ADP
aji-173	178	26	subtle	subtle	ADJ
aji-173	178	27	monoclonal	monoclonal	NOUN
aji-173	178	28	peaks	peak	NOUN
aji-173	178	29	and	and	CCONJ
aji-173	178	30	imbalances	imbalance	NOUN
aji-173	178	31	in	in	ADP
aji-173	178	32	the	the	DET
aji-173	178	33	κ	κ	NOUN
aji-173	178	34	/	/	SYM
aji-173	178	35	λ	λ	NOUN
aji-173	178	36	ratio	ratio	NOUN
aji-173	178	37	ratio	ratio	NOUN
aji-173	178	38	imbalances	imbalance	NOUN
aji-173	178	39	(	(	PUNCT
aji-173	178	40	terpos	terpos	NOUN
aji-173	178	41	&	&	CCONJ
aji-173	178	42	dimopoulos	dimopoulo	NOUN
aji-173	178	43	,	,	PUNCT
aji-173	178	44	2005	2005	NUM
aji-173	178	45	)	)	PUNCT
aji-173	178	46	.	.	PUNCT
aji-173	179	1	these	these	DET
aji-173	179	2	investigations	investigation	NOUN
aji-173	179	3	are	be	AUX
aji-173	179	4	systematically	systematically	ADV
aji-173	179	5	recommended	recommend	VERB
aji-173	179	6	in	in	ADP
aji-173	179	7	the	the	DET
aji-173	179	8	literature	literature	NOUN
aji-173	179	9	and	and	CCONJ
aji-173	179	10	their	their	PRON
aji-173	179	11	importance	importance	NOUN
aji-173	179	12	is	be	AUX
aji-173	179	13	unanimously	unanimously	ADV
aji-173	179	14	recognized	recognize	VERB
aji-173	179	15	,	,	PUNCT
aji-173	179	16	particularly	particularly	ADV
aji-173	179	17	in	in	ADP
aji-173	179	18	the	the	DET
aji-173	179	19	reviews	review	NOUN
aji-173	179	20	by	by	ADP
aji-173	179	21	gertz	gertz	PROPN
aji-173	179	22	(	(	PUNCT
aji-173	179	23	2008	2008	NUM
aji-173	179	24	)	)	PUNCT
aji-173	179	25	and	and	CCONJ
aji-173	179	26	terpos	terpos	PROPN
aji-173	179	27	&	&	CCONJ
aji-173	179	28	dimopoulos	dimopoulos	PROPN
aji-173	179	29	(	(	PUNCT
aji-173	179	30	2005	2005	NUM
aji-173	179	31	)	)	PUNCT
aji-173	179	32	,	,	PUNCT
aji-173	179	33	confirming	confirm	VERB
aji-173	179	34	the	the	DET
aji-173	179	35	relevance	relevance	NOUN
aji-173	179	36	of	of	ADP
aji-173	179	37	our	our	PRON
aji-173	179	38	diagnostic	diagnostic	ADJ
aji-173	179	39	approach	approach	NOUN
aji-173	179	40	(	(	PUNCT
aji-173	179	41	faze	faze	NOUN
aji-173	179	42	,	,	PUNCT
aji-173	179	43	2019	2019	NUM
aji-173	179	44	;	;	PUNCT
aji-173	179	45	borja	borja	PROPN
aji-173	179	46	,	,	PUNCT
aji-173	179	47	meriche	meriche	PROPN
aji-173	179	48	et	et	PROPN
aji-173	179	49	al	al	PROPN
aji-173	179	50	.	.	PROPN
aji-173	179	51	;	;	PUNCT
aji-173	180	1	asian	asian	PROPN
aji-173	180	2	j.	j.	PROPN
aji-173	180	3	immunol	immunol	PROPN
aji-173	180	4	.	.	PROPN
aji-173	180	5	,	,	PUNCT
aji-173	180	6	vol	vol	NOUN
aji-173	180	7	.	.	PROPN
aji-173	180	8	8	8	NUM
aji-173	180	9	,	,	PUNCT
aji-173	180	10	no	no	INTJ
aji-173	180	11	.	.	NOUN
aji-173	180	12	1	1	NUM
aji-173	180	13	,	,	PUNCT
aji-173	180	14	pp	pp	ADJ
aji-173	180	15	.	.	PUNCT
aji-173	181	1	222	222	NUM
aji-173	181	2	-	-	SYM
aji-173	181	3	229	229	NUM
aji-173	181	4	,	,	PUNCT
aji-173	181	5	2025	2025	NUM
aji-173	181	6	;	;	PUNCT
aji-173	181	7	article	article	NOUN
aji-173	181	8	no.aji.141940	no.aji.141940	VERB
aji-173	181	9	227	227	NUM
aji-173	181	10	2011	2011	NUM
aji-173	181	11	)	)	PUNCT
aji-173	181	12	.	.	PUNCT
aji-173	182	1	pregnancy	pregnancy	NOUN
aji-173	182	2	alters	alter	VERB
aji-173	182	3	the	the	DET
aji-173	182	4	immune	immune	ADJ
aji-173	182	5	system	system	NOUN
aji-173	182	6	,	,	PUNCT
aji-173	182	7	inducing	induce	VERB
aji-173	182	8	maternal	maternal	ADJ
aji-173	182	9	-	-	PUNCT
aji-173	182	10	fetal	fetal	NOUN
aji-173	182	11	tolerance	tolerance	NOUN
aji-173	182	12	by	by	ADP
aji-173	182	13	reducing	reduce	VERB
aji-173	182	14	cellular	cellular	ADJ
aji-173	182	15	and	and	CCONJ
aji-173	182	16	humoral	humoral	ADJ
aji-173	182	17	immune	immune	ADJ
aji-173	182	18	responses	response	NOUN
aji-173	182	19	(	(	PUNCT
aji-173	182	20	palumbo	palumbo	X
aji-173	182	21	et	et	PROPN
aji-173	182	22	al	al	PROPN
aji-173	182	23	.	.	PROPN
aji-173	182	24	,	,	PUNCT
aji-173	182	25	2020	2020	NUM
aji-173	182	26	)	)	PUNCT
aji-173	182	27	.	.	PUNCT
aji-173	183	1	this	this	DET
aji-173	183	2	modulation	modulation	NOUN
aji-173	183	3	can	can	AUX
aji-173	183	4	attenuate	attenuate	VERB
aji-173	183	5	the	the	DET
aji-173	183	6	classic	classic	ADJ
aji-173	183	7	symptoms	symptom	NOUN
aji-173	183	8	of	of	ADP
aji-173	183	9	mm	mm	PROPN
aji-173	183	10	(	(	PUNCT
aji-173	183	11	fatigue	fatigue	NOUN
aji-173	183	12	,	,	PUNCT
aji-173	183	13	recurrent	recurrent	ADJ
aji-173	183	14	infections	infection	NOUN
aji-173	183	15	,	,	PUNCT
aji-173	183	16	bone	bone	NOUN
aji-173	183	17	pain	pain	NOUN
aji-173	183	18	)	)	PUNCT
aji-173	183	19	,	,	PUNCT
aji-173	183	20	explaining	explain	VERB
aji-173	183	21	the	the	DET
aji-173	183	22	late	late	ADJ
aji-173	183	23	or	or	CCONJ
aji-173	183	24	incidental	incidental	ADJ
aji-173	183	25	discovery	discovery	NOUN
aji-173	183	26	of	of	ADP
aji-173	183	27	cases	case	NOUN
aji-173	183	28	during	during	ADP
aji-173	183	29	pregnancy	pregnancy	NOUN
aji-173	183	30	—	—	PUNCT
aji-173	183	31	a	a	DET
aji-173	183	32	point	point	NOUN
aji-173	183	33	that	that	SCONJ
aji-173	183	34	our	our	PRON
aji-173	183	35	observation	observation	NOUN
aji-173	183	36	corroborates	corroborate	VERB
aji-173	183	37	in	in	ADP
aji-173	183	38	perfect	perfect	ADJ
aji-173	183	39	agreement	agreement	NOUN
aji-173	183	40	with	with	ADP
aji-173	183	41	the	the	DET
aji-173	183	42	work	work	NOUN
aji-173	183	43	of	of	ADP
aji-173	183	44	mor	mor	PROPN
aji-173	183	45	&	&	CCONJ
aji-173	183	46	cardenas	cardenas	PROPN
aji-173	183	47	(	(	PUNCT
aji-173	183	48	2010	2010	NUM
aji-173	183	49	)	)	PUNCT
aji-173	183	50	and	and	CCONJ
aji-173	183	51	lee	lee	PROPN
aji-173	183	52	et	et	PROPN
aji-173	183	53	al	al	PROPN
aji-173	183	54	.	.	PROPN
aji-173	184	1	(	(	PUNCT
aji-173	184	2	2016	2016	NUM
aji-173	184	3	)	)	PUNCT
aji-173	184	4	(	(	PUNCT
aji-173	185	1	dispenzieri	dispenzieri	ADV
aji-173	185	2	et	et	PROPN
aji-173	185	3	al	al	PROPN
aji-173	185	4	.	.	PROPN
aji-173	185	5	,	,	PUNCT
aji-173	185	6	2019	2019	NUM
aji-173	185	7	;	;	PUNCT
aji-173	185	8	pajor	pajor	NOUN
aji-173	185	9	,	,	PUNCT
aji-173	185	10	1991	1991	NUM
aji-173	185	11	)	)	PUNCT
aji-173	185	12	.	.	PUNCT
aji-173	186	1	from	from	ADP
aji-173	186	2	an	an	DET
aji-173	186	3	immunopathological	immunopathological	ADJ
aji-173	186	4	perspective	perspective	NOUN
aji-173	186	5	,	,	PUNCT
aji-173	186	6	il-6	il-6	PRON
aji-173	186	7	plays	play	VERB
aji-173	186	8	a	a	DET
aji-173	186	9	major	major	ADJ
aji-173	186	10	role	role	NOUN
aji-173	186	11	in	in	ADP
aji-173	186	12	the	the	DET
aji-173	186	13	proliferation	proliferation	NOUN
aji-173	186	14	of	of	ADP
aji-173	186	15	malignant	malignant	ADJ
aji-173	186	16	plasma	plasma	NOUN
aji-173	186	17	cells	cell	NOUN
aji-173	186	18	and	and	CCONJ
aji-173	186	19	in	in	ADP
aji-173	186	20	the	the	DET
aji-173	186	21	development	development	NOUN
aji-173	186	22	of	of	ADP
aji-173	186	23	bone	bone	NOUN
aji-173	186	24	lesions	lesion	NOUN
aji-173	186	25	through	through	ADP
aji-173	186	26	the	the	DET
aji-173	186	27	activation	activation	NOUN
aji-173	186	28	of	of	ADP
aji-173	186	29	osteoclasts	osteoclast	NOUN
aji-173	186	30	(	(	PUNCT
aji-173	186	31	rajkumar	rajkumar	PROPN
aji-173	186	32	,	,	PUNCT
aji-173	186	33	2020	2020	NUM
aji-173	186	34	)	)	PUNCT
aji-173	186	35	.	.	PUNCT
aji-173	187	1	as	as	SCONJ
aji-173	187	2	observed	observe	VERB
aji-173	187	3	in	in	ADP
aji-173	187	4	our	our	PRON
aji-173	187	5	patient	patient	NOUN
aji-173	187	6	,	,	PUNCT
aji-173	187	7	this	this	DET
aji-173	187	8	mechanism	mechanism	NOUN
aji-173	187	9	is	be	AUX
aji-173	187	10	responsible	responsible	ADJ
aji-173	187	11	for	for	ADP
aji-173	187	12	the	the	DET
aji-173	187	13	common	common	ADJ
aji-173	187	14	disabling	disable	VERB
aji-173	187	15	bone	bone	NOUN
aji-173	187	16	complications	complication	NOUN
aji-173	187	17	of	of	ADP
aji-173	187	18	mm	mm	PROPN
aji-173	187	19	,	,	PUNCT
aji-173	187	20	suggesting	suggest	VERB
aji-173	187	21	the	the	DET
aji-173	187	22	need	need	NOUN
aji-173	187	23	for	for	ADP
aji-173	187	24	increased	increase	VERB
aji-173	187	25	vigilance	vigilance	NOUN
aji-173	187	26	,	,	PUNCT
aji-173	187	27	particularly	particularly	ADV
aji-173	187	28	in	in	ADP
aji-173	187	29	the	the	DET
aji-173	187	30	context	context	NOUN
aji-173	187	31	of	of	ADP
aji-173	187	32	pregnancy	pregnancy	NOUN
aji-173	187	33	,	,	PUNCT
aji-173	187	34	where	where	SCONJ
aji-173	187	35	osteoarticular	osteoarticular	ADJ
aji-173	187	36	symptoms	symptom	NOUN
aji-173	187	37	can	can	AUX
aji-173	187	38	be	be	AUX
aji-173	187	39	confused	confuse	VERB
aji-173	187	40	with	with	ADP
aji-173	187	41	physiological	physiological	ADJ
aji-173	187	42	pain	pain	NOUN
aji-173	187	43	associated	associate	VERB
aji-173	187	44	with	with	ADP
aji-173	187	45	pregnancy	pregnancy	NOUN
aji-173	187	46	(	(	PUNCT
aji-173	187	47	terpos	terpos	NOUN
aji-173	187	48	&	&	CCONJ
aji-173	187	49	dimopoulos	dimopoulo	NOUN
aji-173	187	50	,	,	PUNCT
aji-173	187	51	2005	2005	NUM
aji-173	187	52	)	)	PUNCT
aji-173	187	53	.	.	PUNCT
aji-173	188	1	this	this	DET
aji-173	188	2	issue	issue	NOUN
aji-173	188	3	is	be	AUX
aji-173	188	4	discussed	discuss	VERB
aji-173	188	5	at	at	ADP
aji-173	188	6	length	length	NOUN
aji-173	188	7	by	by	ADP
aji-173	188	8	terpos	terpos	NOUN
aji-173	188	9	and	and	CCONJ
aji-173	188	10	dimopoulos	dimopoulo	NOUN
aji-173	188	11	(	(	PUNCT
aji-173	188	12	2005	2005	NUM
aji-173	188	13	)	)	PUNCT
aji-173	188	14	and	and	CCONJ
aji-173	188	15	terpos	terpos	NOUN
aji-173	188	16	et	et	PROPN
aji-173	188	17	al	al	PROPN
aji-173	188	18	.	.	PROPN
aji-173	189	1	(	(	PUNCT
aji-173	189	2	2020	2020	NUM
aji-173	189	3	)	)	PUNCT
aji-173	189	4	(	(	PUNCT
aji-173	189	5	rajkumar	rajkumar	PROPN
aji-173	189	6	,	,	PUNCT
aji-173	189	7	2020	2020	NUM
aji-173	189	8	;	;	PUNCT
aji-173	189	9	elgabry	elgabry	PROPN
aji-173	189	10	et	et	PROPN
aji-173	189	11	al	al	PROPN
aji-173	189	12	.	.	PROPN
aji-173	189	13	,	,	PUNCT
aji-173	189	14	2023	2023	NUM
aji-173	189	15	)	)	PUNCT
aji-173	189	16	.	.	PUNCT
aji-173	190	1	the	the	DET
aji-173	190	2	therapeutic	therapeutic	ADJ
aji-173	190	3	management	management	NOUN
aji-173	190	4	of	of	ADP
aji-173	190	5	mm	mm	PROPN
aji-173	190	6	during	during	ADP
aji-173	190	7	pregnancy	pregnancy	NOUN
aji-173	190	8	remains	remain	VERB
aji-173	190	9	a	a	DET
aji-173	190	10	major	major	ADJ
aji-173	190	11	challenge	challenge	NOUN
aji-173	190	12	.	.	PUNCT
aji-173	191	1	the	the	DET
aji-173	191	2	literature	literature	NOUN
aji-173	191	3	,	,	PUNCT
aji-173	191	4	including	include	VERB
aji-173	191	5	the	the	DET
aji-173	191	6	study	study	NOUN
aji-173	191	7	by	by	ADP
aji-173	191	8	lee	lee	PROPN
aji-173	191	9	et	et	PROPN
aji-173	191	10	al	al	PROPN
aji-173	191	11	.	.	PROPN
aji-173	191	12	(	(	PUNCT
aji-173	191	13	2018	2018	NUM
aji-173	191	14	)	)	PUNCT
aji-173	191	15	,	,	PUNCT
aji-173	191	16	recommends	recommend	VERB
aji-173	191	17	a	a	DET
aji-173	191	18	cautious	cautious	ADJ
aji-173	191	19	approach	approach	NOUN
aji-173	191	20	,	,	PUNCT
aji-173	191	21	generally	generally	ADV
aji-173	191	22	deferring	defer	VERB
aji-173	191	23	active	active	ADJ
aji-173	191	24	treatment	treatment	NOUN
aji-173	191	25	until	until	ADP
aji-173	191	26	after	after	ADP
aji-173	191	27	delivery	delivery	NOUN
aji-173	191	28	to	to	PART
aji-173	191	29	avoid	avoid	VERB
aji-173	191	30	the	the	DET
aji-173	191	31	teratogenic	teratogenic	ADJ
aji-173	191	32	effects	effect	NOUN
aji-173	191	33	of	of	ADP
aji-173	191	34	conventional	conventional	ADJ
aji-173	191	35	chemotherapy	chemotherapy	NOUN
aji-173	191	36	,	,	PUNCT
aji-173	191	37	particularly	particularly	ADV
aji-173	191	38	in	in	ADP
aji-173	191	39	the	the	DET
aji-173	191	40	first	first	ADJ
aji-173	191	41	trimester	trimester	NOUN
aji-173	191	42	(	(	PUNCT
aji-173	191	43	rajkumar	rajkumar	PROPN
aji-173	191	44	,	,	PUNCT
aji-173	191	45	2011	2011	NUM
aji-173	191	46	)	)	PUNCT
aji-173	191	47	.	.	PUNCT
aji-173	192	1	this	this	DET
aji-173	192	2	strategy	strategy	NOUN
aji-173	192	3	,	,	PUNCT
aji-173	192	4	with	with	ADP
aji-173	192	5	close	close	ADJ
aji-173	192	6	multidisciplinary	multidisciplinary	ADJ
aji-173	192	7	follow	follow	NOUN
aji-173	192	8	-	-	PUNCT
aji-173	192	9	up	up	NOUN
aji-173	192	10	,	,	PUNCT
aji-173	192	11	corresponds	correspond	VERB
aji-173	192	12	exactly	exactly	ADV
aji-173	192	13	to	to	ADP
aji-173	192	14	the	the	DET
aji-173	192	15	management	management	NOUN
aji-173	192	16	protocol	protocol	NOUN
aji-173	192	17	we	we	PRON
aji-173	192	18	applied	apply	VERB
aji-173	192	19	,	,	PUNCT
aji-173	192	20	reflecting	reflect	VERB
aji-173	192	21	perfect	perfect	ADJ
aji-173	192	22	alignment	alignment	NOUN
aji-173	192	23	with	with	ADP
aji-173	192	24	current	current	ADJ
aji-173	192	25	best	good	ADJ
aji-173	192	26	practices	practice	NOUN
aji-173	192	27	(	(	PUNCT
aji-173	192	28	rajkumar	rajkumar	PROPN
aji-173	192	29	,	,	PUNCT
aji-173	192	30	2020	2020	NUM
aji-173	192	31	;	;	PUNCT
aji-173	192	32	smith	smith	PROPN
aji-173	192	33	,	,	PUNCT
aji-173	192	34	2021	2021	NUM
aji-173	192	35	)	)	PUNCT
aji-173	192	36	.	.	PUNCT
aji-173	193	1	the	the	DET
aji-173	193	2	standard	standard	ADJ
aji-173	193	3	postpartum	postpartum	NOUN
aji-173	193	4	treatment	treatment	NOUN
aji-173	193	5	for	for	ADP
aji-173	193	6	symptomatic	symptomatic	ADJ
aji-173	193	7	multiple	multiple	ADJ
aji-173	193	8	myeloma	myeloma	NOUN
aji-173	193	9	is	be	AUX
aji-173	193	10	the	the	DET
aji-173	193	11	combined	combined	ADJ
aji-173	193	12	vtd	vtd	PROPN
aji-173	193	13	protocol	protocol	NOUN
aji-173	193	14	(	(	PUNCT
aji-173	193	15	bortezomib	bortezomib	NOUN
aji-173	193	16	,	,	PUNCT
aji-173	193	17	thalidomide	thalidomide	NOUN
aji-173	193	18	,	,	PUNCT
aji-173	193	19	dexamethasone	dexamethasone	NOUN
aji-173	193	20	)	)	PUNCT
aji-173	193	21	,	,	PUNCT
aji-173	193	22	recognized	recognize	VERB
aji-173	193	23	for	for	ADP
aji-173	193	24	its	its	PRON
aji-173	193	25	efficacy	efficacy	NOUN
aji-173	193	26	and	and	CCONJ
aji-173	193	27	good	good	ADJ
aji-173	193	28	tolerance	tolerance	NOUN
aji-173	193	29	,	,	PUNCT
aji-173	193	30	validated	validate	VERB
aji-173	193	31	by	by	ADP
aji-173	193	32	several	several	ADJ
aji-173	193	33	studies	study	NOUN
aji-173	193	34	,	,	PUNCT
aji-173	193	35	including	include	VERB
aji-173	193	36	that	that	PRON
aji-173	193	37	of	of	ADP
aji-173	193	38	palumbo	palumbo	PROPN
aji-173	193	39	et	et	PROPN
aji-173	193	40	al	al	PROPN
aji-173	193	41	.	.	PROPN
aji-173	194	1	(	(	PUNCT
aji-173	194	2	2020	2020	NUM
aji-173	194	3	)	)	PUNCT
aji-173	194	4	.	.	PUNCT
aji-173	195	1	new	new	ADJ
aji-173	195	2	therapeutic	therapeutic	ADJ
aji-173	195	3	options	option	NOUN
aji-173	195	4	,	,	PUNCT
aji-173	195	5	such	such	ADJ
aji-173	195	6	as	as	ADP
aji-173	195	7	monoclonal	monoclonal	NOUN
aji-173	195	8	antibodies	antibody	NOUN
aji-173	195	9	and	and	CCONJ
aji-173	195	10	newer	new	ADJ
aji-173	195	11	proteasome	proteasome	NOUN
aji-173	195	12	inhibitors	inhibitor	NOUN
aji-173	195	13	,	,	PUNCT
aji-173	195	14	are	be	AUX
aji-173	195	15	currently	currently	ADV
aji-173	195	16	being	be	AUX
aji-173	195	17	evaluated	evaluate	VERB
aji-173	195	18	,	,	PUNCT
aji-173	195	19	although	although	SCONJ
aji-173	195	20	data	datum	NOUN
aji-173	195	21	in	in	ADP
aji-173	195	22	pregnant	pregnant	ADJ
aji-173	195	23	women	woman	NOUN
aji-173	195	24	remain	remain	VERB
aji-173	195	25	limited	limited	ADJ
aji-173	195	26	,	,	PUNCT
aji-173	195	27	as	as	SCONJ
aji-173	195	28	highlighted	highlight	VERB
aji-173	195	29	by	by	ADP
aji-173	195	30	dispenzieri	dispenzieri	PROPN
aji-173	195	31	et	et	PROPN
aji-173	195	32	al	al	PROPN
aji-173	195	33	.	.	PROPN
aji-173	196	1	(	(	PUNCT
aji-173	196	2	2019	2019	NUM
aji-173	196	3	)	)	PUNCT
aji-173	196	4	.	.	PUNCT
aji-173	197	1	the	the	DET
aji-173	197	2	protocol	protocol	NOUN
aji-173	197	3	used	use	VERB
aji-173	197	4	in	in	ADP
aji-173	197	5	this	this	DET
aji-173	197	6	case	case	NOUN
aji-173	197	7	is	be	AUX
aji-173	197	8	consistent	consistent	ADJ
aji-173	197	9	with	with	ADP
aji-173	197	10	current	current	ADJ
aji-173	197	11	recommendations	recommendation	NOUN
aji-173	197	12	and	and	CCONJ
aji-173	197	13	advances	advance	NOUN
aji-173	197	14	in	in	ADP
aji-173	197	15	the	the	DET
aji-173	197	16	treatment	treatment	NOUN
aji-173	197	17	of	of	ADP
aji-173	197	18	multiple	multiple	ADJ
aji-173	197	19	myeloma	myeloma	NOUN
aji-173	197	20	.	.	PUNCT
aji-173	198	1	finally	finally	ADV
aji-173	198	2	,	,	PUNCT
aji-173	198	3	the	the	DET
aji-173	198	4	importance	importance	NOUN
aji-173	198	5	of	of	ADP
aji-173	198	6	early	early	ADJ
aji-173	198	7	diagnosis	diagnosis	NOUN
aji-173	198	8	in	in	ADP
aji-173	198	9	cases	case	NOUN
aji-173	198	10	of	of	ADP
aji-173	198	11	persistent	persistent	ADJ
aji-173	198	12	anemia	anemia	NOUN
aji-173	198	13	in	in	ADP
aji-173	198	14	pregnant	pregnant	ADJ
aji-173	198	15	women	woman	NOUN
aji-173	198	16	,	,	PUNCT
aji-173	198	17	as	as	SCONJ
aji-173	198	18	highlighted	highlight	VERB
aji-173	198	19	in	in	ADP
aji-173	198	20	our	our	PRON
aji-173	198	21	case	case	NOUN
aji-173	198	22	,	,	PUNCT
aji-173	198	23	is	be	AUX
aji-173	198	24	shared	share	VERB
aji-173	198	25	by	by	ADP
aji-173	198	26	many	many	ADJ
aji-173	198	27	authors	author	NOUN
aji-173	198	28	(	(	PUNCT
aji-173	198	29	terpos,2020a	terpos,2020a	NOUN
aji-173	198	30	,	,	PUNCT
aji-173	198	31	2020b	2020b	NUM
aji-173	198	32	)	)	PUNCT
aji-173	198	33	.	.	PUNCT
aji-173	199	1	increased	increase	VERB
aji-173	199	2	awareness	awareness	NOUN
aji-173	199	3	among	among	ADP
aji-173	199	4	clinicians	clinician	NOUN
aji-173	199	5	to	to	PART
aji-173	199	6	include	include	VERB
aji-173	199	7	specific	specific	ADJ
aji-173	199	8	immunological	immunological	ADJ
aji-173	199	9	tests	test	NOUN
aji-173	199	10	is	be	AUX
aji-173	199	11	necessary	necessary	ADJ
aji-173	199	12	.	.	PUNCT
aji-173	200	1	4	4	X
aji-173	200	2	.	.	X
aji-173	200	3	conclusion	conclusion	NOUN
aji-173	200	4	symptomatic	symptomatic	ADJ
aji-173	200	5	multiple	multiple	ADJ
aji-173	200	6	myeloma	myeloma	NOUN
aji-173	200	7	during	during	ADP
aji-173	200	8	pregnancy	pregnancy	NOUN
aji-173	200	9	represents	represent	VERB
aji-173	200	10	an	an	DET
aji-173	200	11	exceptionally	exceptionally	ADV
aji-173	200	12	rare	rare	ADJ
aji-173	200	13	and	and	CCONJ
aji-173	200	14	challenging	challenge	VERB
aji-173	200	15	clinical	clinical	ADJ
aji-173	200	16	condition	condition	NOUN
aji-173	200	17	.	.	PUNCT
aji-173	201	1	its	its	PRON
aji-173	201	2	diagnosis	diagnosis	NOUN
aji-173	201	3	is	be	AUX
aji-173	201	4	often	often	ADV
aji-173	201	5	delayed	delay	VERB
aji-173	201	6	because	because	SCONJ
aji-173	201	7	the	the	DET
aji-173	201	8	presenting	present	VERB
aji-173	201	9	symptoms	symptom	NOUN
aji-173	201	10	(	(	PUNCT
aji-173	201	11	fatigue	fatigue	NOUN
aji-173	201	12	,	,	PUNCT
aji-173	201	13	bone	bone	NOUN
aji-173	201	14	pain	pain	NOUN
aji-173	201	15	,	,	PUNCT
aji-173	201	16	anemia	anemia	NOUN
aji-173	201	17	)	)	PUNCT
aji-173	201	18	are	be	AUX
aji-173	201	19	frequently	frequently	ADV
aji-173	201	20	misinterpreted	misinterpret	VERB
aji-173	201	21	as	as	ADP
aji-173	201	22	physiological	physiological	ADJ
aji-173	201	23	changes	change	NOUN
aji-173	201	24	of	of	ADP
aji-173	201	25	pregnancy.moreover	pregnancy.moreover	NOUN
aji-173	201	26	,	,	PUNCT
aji-173	201	27	the	the	DET
aji-173	201	28	maternal	maternal	ADJ
aji-173	201	29	immune	immune	ADJ
aji-173	201	30	alterations	alteration	NOUN
aji-173	201	31	associated	associate	VERB
aji-173	201	32	with	with	ADP
aji-173	201	33	feto	feto	VERB
aji-173	201	34	-	-	PUNCT
aji-173	201	35	maternal	maternal	ADJ
aji-173	201	36	tolerance	tolerance	NOUN
aji-173	201	37	further	far	ADV
aji-173	201	38	complicate	complicate	VERB
aji-173	201	39	both	both	CCONJ
aji-173	201	40	the	the	DET
aji-173	201	41	clinical	clinical	ADJ
aji-173	201	42	assessment	assessment	NOUN
aji-173	201	43	and	and	CCONJ
aji-173	201	44	the	the	DET
aji-173	201	45	interpretation	interpretation	NOUN
aji-173	201	46	of	of	ADP
aji-173	201	47	laboratory	laboratory	NOUN
aji-173	201	48	findings	finding	NOUN
aji-173	201	49	.	.	PUNCT
aji-173	202	1	nevertheless	nevertheless	ADV
aji-173	202	2	,	,	PUNCT
aji-173	202	3	certain	certain	ADJ
aji-173	202	4	warning	warning	NOUN
aji-173	202	5	signs	sign	NOUN
aji-173	202	6	should	should	AUX
aji-173	202	7	prompt	prompt	VERB
aji-173	202	8	further	further	ADJ
aji-173	202	9	investigation	investigation	NOUN
aji-173	202	10	:	:	PUNCT
aji-173	202	11	a	a	DET
aji-173	202	12	persistent	persistent	ADJ
aji-173	202	13	,	,	PUNCT
aji-173	202	14	unexplained	unexplained	ADJ
aji-173	202	15	anemia	anemia	NOUN
aji-173	202	16	refractory	refractory	NOUN
aji-173	202	17	to	to	PART
aji-173	202	18	iron	iron	NOUN
aji-173	202	19	supplementation	supplementation	NOUN
aji-173	202	20	,	,	PUNCT
aji-173	202	21	when	when	SCONJ
aji-173	202	22	associated	associate	VERB
aji-173	202	23	with	with	ADP
aji-173	202	24	the	the	DET
aji-173	202	25	detection	detection	NOUN
aji-173	202	26	of	of	ADP
aji-173	202	27	a	a	DET
aji-173	202	28	monoclonal	monoclonal	NOUN
aji-173	202	29	spike	spike	NOUN
aji-173	202	30	on	on	ADP
aji-173	202	31	serum	serum	NOUN
aji-173	202	32	protein	protein	NOUN
aji-173	202	33	electrophoresis	electrophoresis	NOUN
aji-173	202	34	,	,	PUNCT
aji-173	202	35	strongly	strongly	ADV
aji-173	202	36	suggests	suggest	VERB
aji-173	202	37	an	an	DET
aji-173	202	38	underlying	underlie	VERB
aji-173	202	39	plasma	plasma	NOUN
aji-173	202	40	cell	cell	NOUN
aji-173	202	41	dyscrasia	dyscrasia	PROPN
aji-173	202	42	.	.	PUNCT
aji-173	203	1	in	in	ADP
aji-173	203	2	such	such	ADJ
aji-173	203	3	cases	case	NOUN
aji-173	203	4	,	,	PUNCT
aji-173	203	5	a	a	DET
aji-173	203	6	comprehensive	comprehensive	ADJ
aji-173	203	7	immunological	immunological	ADJ
aji-173	203	8	work	work	NOUN
aji-173	203	9	-	-	PUNCT
aji-173	203	10	up	up	NOUN
aji-173	203	11	(	(	PUNCT
aji-173	203	12	including	include	VERB
aji-173	203	13	immunofixation	immunofixation	NOUN
aji-173	203	14	,	,	PUNCT
aji-173	203	15	quantitative	quantitative	ADJ
aji-173	203	16	immunoglobulins	immunoglobulin	NOUN
aji-173	203	17	,	,	PUNCT
aji-173	203	18	and	and	CCONJ
aji-173	203	19	free	free	ADJ
aji-173	203	20	light	light	NOUN
aji-173	203	21	chain	chain	NOUN
aji-173	203	22	assay	assay	NOUN
aji-173	203	23	)	)	PUNCT
aji-173	203	24	is	be	AUX
aji-173	203	25	mandatory	mandatory	ADJ
aji-173	203	26	for	for	ADP
aji-173	203	27	the	the	DET
aji-173	203	28	biological	biological	ADJ
aji-173	203	29	detection	detection	NOUN
aji-173	203	30	of	of	ADP
aji-173	203	31	multiple	multiple	ADJ
aji-173	203	32	myeloma	myeloma	NOUN
aji-173	203	33	.	.	PUNCT
aji-173	204	1	from	from	ADP
aji-173	204	2	a	a	DET
aji-173	204	3	therapeutic	therapeutic	ADJ
aji-173	204	4	perspective	perspective	NOUN
aji-173	204	5	,	,	PUNCT
aji-173	204	6	postponing	postpone	VERB
aji-173	204	7	chemotherapy	chemotherapy	NOUN
aji-173	204	8	until	until	SCONJ
aji-173	204	9	the	the	DET
aji-173	204	10	postpartum	postpartum	NOUN
aji-173	204	11	period	period	NOUN
aji-173	204	12	is	be	AUX
aji-173	204	13	generally	generally	ADV
aji-173	204	14	recommended	recommend	VERB
aji-173	204	15	in	in	ADP
aji-173	204	16	order	order	NOUN
aji-173	204	17	to	to	PART
aji-173	204	18	minimize	minimize	VERB
aji-173	204	19	teratogenic	teratogenic	ADJ
aji-173	204	20	risks	risk	NOUN
aji-173	204	21	to	to	ADP
aji-173	204	22	the	the	DET
aji-173	204	23	fetus	fetus	NOUN
aji-173	204	24	.	.	PUNCT
aji-173	205	1	during	during	ADP
aji-173	205	2	pregnancy	pregnancy	NOUN
aji-173	205	3	,	,	PUNCT
aji-173	205	4	strict	strict	ADJ
aji-173	205	5	multidisciplinary	multidisciplinary	ADJ
aji-173	205	6	monitoring	monitoring	NOUN
aji-173	205	7	involving	involve	VERB
aji-173	205	8	hematologists	hematologist	NOUN
aji-173	205	9	,	,	PUNCT
aji-173	205	10	obstetricians	obstetrician	NOUN
aji-173	205	11	,	,	PUNCT
aji-173	205	12	neonatologists	neonatologist	NOUN
aji-173	205	13	,	,	PUNCT
aji-173	205	14	and	and	CCONJ
aji-173	205	15	anesthesiologists	anesthesiologist	NOUN
aji-173	205	16	is	be	AUX
aji-173	205	17	required	require	VERB
aji-173	205	18	to	to	PART
aji-173	205	19	maintain	maintain	VERB
aji-173	205	20	maternal	maternal	ADJ
aji-173	205	21	and	and	CCONJ
aji-173	205	22	fetal	fetal	ADJ
aji-173	205	23	stability	stability	NOUN
aji-173	205	24	.	.	PUNCT
aji-173	206	1	after	after	ADP
aji-173	206	2	delivery	delivery	NOUN
aji-173	206	3	,	,	PUNCT
aji-173	206	4	treatment	treatment	NOUN
aji-173	206	5	with	with	ADP
aji-173	206	6	the	the	DET
aji-173	206	7	vtd	vtd	ADJ
aji-173	206	8	protocol	protocol	NOUN
aji-173	206	9	(	(	PUNCT
aji-173	206	10	bortezomib	bortezomib	NOUN
aji-173	206	11	,	,	PUNCT
aji-173	206	12	thalidomide	thalidomide	NOUN
aji-173	206	13	,	,	PUNCT
aji-173	206	14	dexamethasone	dexamethasone	NOUN
aji-173	206	15	)	)	PUNCT
aji-173	206	16	has	have	AUX
aji-173	206	17	proven	prove	VERB
aji-173	206	18	to	to	PART
aji-173	206	19	be	be	AUX
aji-173	206	20	both	both	CCONJ
aji-173	206	21	effective	effective	ADJ
aji-173	206	22	and	and	CCONJ
aji-173	206	23	well	well	ADV
aji-173	206	24	tolerated	tolerate	VERB
aji-173	206	25	,	,	PUNCT
aji-173	206	26	leading	lead	VERB
aji-173	206	27	to	to	ADP
aji-173	206	28	complete	complete	ADJ
aji-173	206	29	remission	remission	NOUN
aji-173	206	30	and	and	CCONJ
aji-173	206	31	ensuring	ensure	VERB
aji-173	206	32	a	a	DET
aji-173	206	33	favorable	favorable	ADJ
aji-173	206	34	prognosis	prognosis	NOUN
aji-173	206	35	.	.	PUNCT
aji-173	207	1	finally	finally	ADV
aji-173	207	2	,	,	PUNCT
aji-173	207	3	the	the	DET
aji-173	207	4	management	management	NOUN
aji-173	207	5	of	of	ADP
aji-173	207	6	multiple	multiple	ADJ
aji-173	207	7	myeloma	myeloma	NOUN
aji-173	207	8	during	during	ADP
aji-173	207	9	pregnancy	pregnancy	NOUN
aji-173	207	10	requires	require	VERB
aji-173	207	11	a	a	DET
aji-173	207	12	personalized	personalized	ADJ
aji-173	207	13	and	and	CCONJ
aji-173	207	14	multidisciplinary	multidisciplinary	ADJ
aji-173	207	15	approach	approach	NOUN
aji-173	207	16	,	,	PUNCT
aji-173	207	17	carefully	carefully	ADV
aji-173	207	18	balancing	balance	VERB
aji-173	207	19	maternal	maternal	ADJ
aji-173	207	20	safety	safety	NOUN
aji-173	207	21	,	,	PUNCT
aji-173	207	22	fetal	fetal	ADJ
aji-173	207	23	protection	protection	NOUN
aji-173	207	24	,	,	PUNCT
aji-173	207	25	and	and	CCONJ
aji-173	207	26	the	the	DET
aji-173	207	27	optimization	optimization	NOUN
aji-173	207	28	of	of	ADP
aji-173	207	29	therapeutic	therapeutic	ADJ
aji-173	207	30	outcomes	outcome	NOUN
aji-173	207	31	in	in	ADP
aji-173	207	32	the	the	DET
aji-173	207	33	postpartum	postpartum	NOUN
aji-173	207	34	period	period	NOUN
aji-173	207	35	.	.	PUNCT
aji-173	208	1	consent	consent	NOUN
aji-173	208	2	as	as	ADP
aji-173	208	3	per	per	ADP
aji-173	208	4	international	international	ADJ
aji-173	208	5	standards	standard	NOUN
aji-173	208	6	or	or	CCONJ
aji-173	208	7	university	university	NOUN
aji-173	208	8	standards	standard	NOUN
aji-173	208	9	,	,	PUNCT
aji-173	208	10	patient(s	patient(s	PROPN
aji-173	208	11	)	)	PUNCT
aji-173	208	12	written	write	VERB
aji-173	208	13	consent	consent	NOUN
aji-173	208	14	has	have	AUX
aji-173	208	15	been	be	AUX
aji-173	208	16	collected	collect	VERB
aji-173	208	17	and	and	CCONJ
aji-173	208	18	preserved	preserve	VERB
aji-173	208	19	by	by	ADP
aji-173	208	20	the	the	DET
aji-173	208	21	author(s	author(s	NOUN
aji-173	208	22	)	)	PUNCT
aji-173	208	23	.	.	PUNCT
aji-173	209	1	ethical	ethical	ADJ
aji-173	209	2	approval	approval	NOUN
aji-173	209	3	as	as	ADP
aji-173	209	4	per	per	ADP
aji-173	209	5	international	international	ADJ
aji-173	209	6	standards	standard	NOUN
aji-173	209	7	or	or	CCONJ
aji-173	209	8	university	university	NOUN
aji-173	209	9	standards	standard	NOUN
aji-173	209	10	written	write	VERB
aji-173	209	11	ethical	ethical	ADJ
aji-173	209	12	approval	approval	NOUN
aji-173	209	13	has	have	AUX
aji-173	209	14	been	be	AUX
aji-173	209	15	collected	collect	VERB
aji-173	209	16	and	and	CCONJ
aji-173	209	17	preserved	preserve	VERB
aji-173	209	18	by	by	ADP
aji-173	209	19	the	the	DET
aji-173	209	20	author(s	author(s	NOUN
aji-173	209	21	)	)	PUNCT
aji-173	209	22	.	.	PUNCT
aji-173	210	1	meriche	meriche	PROPN
aji-173	210	2	et	et	PROPN
aji-173	210	3	al	al	PROPN
aji-173	210	4	.	.	PROPN
aji-173	210	5	;	;	PUNCT
aji-173	210	6	asian	asian	PROPN
aji-173	210	7	j.	j.	PROPN
aji-173	210	8	immunol	immunol	PROPN
aji-173	210	9	.	.	PROPN
aji-173	210	10	,	,	PUNCT
aji-173	210	11	vol	vol	NOUN
aji-173	210	12	.	.	PROPN
aji-173	210	13	8	8	NUM
aji-173	210	14	,	,	PUNCT
aji-173	210	15	no	no	INTJ
aji-173	210	16	.	.	NOUN
aji-173	210	17	1	1	NUM
aji-173	210	18	,	,	PUNCT
aji-173	210	19	pp	pp	ADJ
aji-173	210	20	.	.	PUNCT
aji-173	211	1	222	222	NUM
aji-173	211	2	-	-	SYM
aji-173	211	3	229	229	NUM
aji-173	211	4	,	,	PUNCT
aji-173	211	5	2025	2025	NUM
aji-173	211	6	;	;	PUNCT
aji-173	211	7	article	article	NOUN
aji-173	211	8	no.aji.141940	no.aji.141940	NOUN
aji-173	211	9	228	228	NUM
aji-173	211	10	disclaimer	disclaimer	NOUN
aji-173	211	11	(	(	PUNCT
aji-173	211	12	artificial	artificial	ADJ
aji-173	211	13	intelligence	intelligence	NOUN
aji-173	211	14	)	)	PUNCT
aji-173	211	15	author(s	author(s	NOUN
aji-173	211	16	)	)	PUNCT
aji-173	211	17	hereby	hereby	ADV
aji-173	211	18	declare	declare	VERB
aji-173	211	19	that	that	SCONJ
aji-173	211	20	generative	generative	ADJ
aji-173	211	21	ai	ai	VERB
aji-173	211	22	technologies	technology	NOUN
aji-173	211	23	such	such	ADJ
aji-173	211	24	as	as	ADP
aji-173	211	25	large	large	ADJ
aji-173	211	26	language	language	NOUN
aji-173	211	27	models	model	NOUN
aji-173	211	28	,	,	PUNCT
aji-173	211	29	etc	etc	X
aji-173	211	30	.	.	X
aji-173	211	31	have	have	AUX
aji-173	211	32	been	be	AUX
aji-173	211	33	used	use	VERB
aji-173	211	34	during	during	ADP
aji-173	211	35	the	the	DET
aji-173	211	36	writing	writing	NOUN
aji-173	211	37	or	or	CCONJ
aji-173	211	38	editing	editing	NOUN
aji-173	211	39	of	of	ADP
aji-173	211	40	manuscripts	manuscript	NOUN
aji-173	211	41	.	.	PUNCT
aji-173	212	1	this	this	DET
aji-173	212	2	explanation	explanation	NOUN
aji-173	212	3	will	will	AUX
aji-173	212	4	include	include	VERB
aji-173	212	5	the	the	DET
aji-173	212	6	name	name	NOUN
aji-173	212	7	,	,	PUNCT
aji-173	212	8	version	version	NOUN
aji-173	212	9	,	,	PUNCT
aji-173	212	10	model	model	NOUN
aji-173	212	11	,	,	PUNCT
aji-173	212	12	and	and	CCONJ
aji-173	212	13	source	source	NOUN
aji-173	212	14	of	of	ADP
aji-173	212	15	the	the	DET
aji-173	212	16	generative	generative	NOUN
aji-173	212	17	ai	ai	VERB
aji-173	212	18	technology	technology	NOUN
aji-173	212	19	and	and	CCONJ
aji-173	212	20	as	as	ADV
aji-173	212	21	well	well	ADV
aji-173	212	22	as	as	ADP
aji-173	212	23	all	all	DET
aji-173	212	24	input	input	NOUN
aji-173	212	25	prompts	prompt	NOUN
aji-173	212	26	provided	provide	VERB
aji-173	212	27	to	to	ADP
aji-173	212	28	the	the	DET
aji-173	212	29	generative	generative	NOUN
aji-173	212	30	ai	ai	VERB
aji-173	212	31	technology	technology	NOUN
aji-173	212	32	details	detail	NOUN
aji-173	212	33	of	of	ADP
aji-173	212	34	the	the	DET
aji-173	212	35	ai	ai	NOUN
aji-173	212	36	usage	usage	NOUN
aji-173	212	37	are	be	AUX
aji-173	212	38	given	give	VERB
aji-173	212	39	below	below	ADP
aji-173	212	40	:	:	PUNCT
aji-173	212	41	1	1	NUM
aji-173	212	42	.	.	X
aji-173	212	43	language	language	NOUN
aji-173	212	44	and	and	CCONJ
aji-173	212	45	style	style	NOUN
aji-173	212	46	enhancement	enhancement	NOUN
aji-173	212	47	2	2	NUM
aji-173	212	48	.	.	PUNCT
aji-173	213	1	aide	aide	PROPN
aji-173	213	2	à	à	X
aji-173	213	3	la	la	X
aji-173	213	4	traduction	traduction	PROPN
aji-173	213	5	3	3	X
aji-173	213	6	.	.	PUNCT
aji-173	213	7	assistance	assistance	NOUN
aji-173	213	8	in	in	ADP
aji-173	213	9	idea	idea	NOUN
aji-173	213	10	generation	generation	NOUN
aji-173	213	11	acknowledgements	acknowledgement	NOUN
aji-173	213	12	we	we	PRON
aji-173	213	13	would	would	AUX
aji-173	213	14	like	like	VERB
aji-173	213	15	to	to	PART
aji-173	213	16	thank	thank	VERB
aji-173	213	17	the	the	DET
aji-173	213	18	nephrology	nephrology	NOUN
aji-173	213	19	,	,	PUNCT
aji-173	213	20	immunology	immunology	NOUN
aji-173	213	21	,	,	PUNCT
aji-173	213	22	and	and	CCONJ
aji-173	213	23	obstetrics	obstetric	NOUN
aji-173	213	24	and	and	CCONJ
aji-173	213	25	gynecology	gynecology	NOUN
aji-173	213	26	teams	team	NOUN
aji-173	213	27	for	for	ADP
aji-173	213	28	their	their	PRON
aji-173	213	29	valuable	valuable	ADJ
aji-173	213	30	collaboration	collaboration	NOUN
aji-173	213	31	.	.	PUNCT
aji-173	214	1	competing	compete	VERB
aji-173	214	2	interests	interest	NOUN
aji-173	214	3	authors	author	NOUN
aji-173	214	4	have	have	AUX
aji-173	214	5	declared	declare	VERB
aji-173	214	6	that	that	SCONJ
aji-173	214	7	no	no	DET
aji-173	214	8	competing	compete	VERB
aji-173	214	9	interests	interest	NOUN
aji-173	214	10	exist	exist	VERB
aji-173	214	11	.	.	PUNCT
aji-173	215	1	references	reference	NOUN
aji-173	215	2	abdellah	abdellah	PROPN
aji-173	215	3	,	,	PUNCT
aji-173	215	4	n.	n.	PROPN
aji-173	215	5	,	,	PUNCT
aji-173	215	6	et	et	PROPN
aji-173	215	7	al	al	PROPN
aji-173	215	8	.	.	PROPN
aji-173	215	9	(	(	PUNCT
aji-173	215	10	2020	2020	NUM
aji-173	215	11	)	)	PUNCT
aji-173	215	12	.	.	PUNCT
aji-173	216	1	implications	implication	NOUN
aji-173	216	2	of	of	ADP
aji-173	216	3	myc	myc	NOUN
aji-173	216	4	rearrangements	rearrangement	NOUN
aji-173	216	5	in	in	ADP
aji-173	216	6	newly	newly	ADV
aji-173	216	7	diagnosed	diagnose	VERB
aji-173	216	8	multiple	multiple	ADJ
aji-173	216	9	myeloma	myeloma	NOUN
aji-173	216	10	.	.	PUNCT
aji-173	217	1	clinical	clinical	ADJ
aji-173	217	2	cancer	cancer	NOUN
aji-173	217	3	research	research	NOUN
aji-173	217	4	,	,	PUNCT
aji-173	217	5	26(24	26(24	NUM
aji-173	217	6	)	)	PUNCT
aji-173	217	7	,	,	PUNCT
aji-173	217	8	6581–6588	6581–6588	X
aji-173	217	9	.	.	PUNCT
aji-173	218	1	borja	borja	PROPN
aji-173	218	2	,	,	PUNCT
aji-173	218	3	d.	d.	PROPN
aji-173	218	4	(	(	PUNCT
aji-173	218	5	2011	2011	NUM
aji-173	218	6	)	)	PUNCT
aji-173	218	7	.	.	PUNCT
aji-173	219	1	multiple	multiple	ADJ
aji-173	219	2	myeloma	myeloma	NOUN
aji-173	219	3	and	and	CCONJ
aji-173	219	4	pregnancy	pregnancy	NOUN
aji-173	219	5	:	:	PUNCT
aji-173	219	6	a	a	DET
aji-173	219	7	case	case	NOUN
aji-173	219	8	report	report	NOUN
aji-173	219	9	and	and	CCONJ
aji-173	219	10	literature	literature	PROPN
aji-173	219	11	review	review	PROPN
aji-173	219	12	.	.	PUNCT
aji-173	220	1	archives	archive	NOUN
aji-173	220	2	of	of	ADP
aji-173	220	3	gynecology	gynecology	NOUN
aji-173	220	4	and	and	CCONJ
aji-173	220	5	obstetrics	obstetric	NOUN
aji-173	220	6	,	,	PUNCT
aji-173	220	7	284(4	284(4	NUM
aji-173	220	8	)	)	PUNCT
aji-173	220	9	,	,	PUNCT
aji-173	220	10	945–950	945–950	NUM
aji-173	220	11	.	.	PUNCT
aji-173	221	1	https://doi.org/10.1007/s00404-011-1985-8	https://doi.org/10.1007/s00404-011-1985-8	NUM
aji-173	221	2	dispenzieri	dispenzieri	ADJ
aji-173	221	3	,	,	PUNCT
aji-173	221	4	a.	a.	PROPN
aji-173	221	5	,	,	PUNCT
aji-173	221	6	et	et	PROPN
aji-173	221	7	al	al	PROPN
aji-173	221	8	.	.	PROPN
aji-173	222	1	(	(	PUNCT
aji-173	222	2	2019	2019	NUM
aji-173	222	3	)	)	PUNCT
aji-173	222	4	.	.	PUNCT
aji-173	223	1	emerging	emerge	VERB
aji-173	223	2	therapies	therapy	NOUN
aji-173	223	3	in	in	ADP
aji-173	223	4	multiple	multiple	ADJ
aji-173	223	5	myeloma	myeloma	NOUN
aji-173	223	6	.	.	PUNCT
aji-173	224	1	nature	nature	NOUN
aji-173	224	2	reviews	review	VERB
aji-173	224	3	clinical	clinical	ADJ
aji-173	224	4	oncology	oncology	NOUN
aji-173	224	5	,	,	PUNCT
aji-173	224	6	16(12	16(12	NUM
aji-173	224	7	)	)	PUNCT
aji-173	224	8	,	,	PUNCT
aji-173	225	1	695–710	695–710	NUM
aji-173	225	2	.	.	PUNCT
aji-173	226	1	durand	durand	NOUN
aji-173	226	2	,	,	PUNCT
aji-173	226	3	r	r	PROPN
aji-173	226	4	et	et	NOUN
aji-173	226	5	al.(2024	al.(2024	NOUN
aji-173	226	6	)	)	PUNCT
aji-173	226	7	.	.	PUNCT
aji-173	227	1	combined	combine	VERB
aji-173	227	2	inhibition	inhibition	NOUN
aji-173	227	3	of	of	ADP
aji-173	227	4	ctps1and	ctps1and	NOUN
aji-173	227	5	atr	atr	NOUN
aji-173	227	6	is	be	AUX
aji-173	227	7	metabolic	metabolic	NOUN
aji-173	227	8	vulnerability	vulnerability	NOUN
aji-173	227	9	in	in	ADP
aji-173	227	10	p53	p53	NOUN
aji-173	227	11	deficient	deficient	ADJ
aji-173	227	12	myeloma	myeloma	NOUN
aji-173	227	13	cells	cell	NOUN
aji-173	227	14	.	.	PUNCT
aji-173	228	1	hemasphere	hemasphere	ADV
aji-173	228	2	,	,	PUNCT
aji-173	228	3	oct.8;8(10):e70016	oct.8;8(10):e70016	PROPN
aji-173	228	4	.	.	PUNCT
aji-173	229	1	elgabry	elgabry	PROPN
aji-173	229	2	,	,	PUNCT
aji-173	229	3	g.	g.	PROPN
aji-173	229	4	,	,	PUNCT
aji-173	229	5	spencer	spencer	PROPN
aji-173	229	6	,	,	PUNCT
aji-173	229	7	l.	l.	PROPN
aji-173	229	8	,	,	PUNCT
aji-173	229	9	siddiqi	siddiqi	PROPN
aji-173	229	10	,	,	PUNCT
aji-173	229	11	h.	h.	PROPN
aji-173	229	12	,	,	PUNCT
aji-173	229	13	ojha	ojha	PROPN
aji-173	229	14	,	,	PUNCT
aji-173	229	15	s.	s.	PROPN
aji-173	229	16	,	,	PUNCT
aji-173	229	17	&	&	CCONJ
aji-173	229	18	wandroo	wandroo	PROPN
aji-173	229	19	,	,	PUNCT
aji-173	229	20	f.	f.	PROPN
aji-173	229	21	(	(	PUNCT
aji-173	229	22	2023	2023	NUM
aji-173	229	23	)	)	PUNCT
aji-173	229	24	.	.	PUNCT
aji-173	230	1	a	a	DET
aji-173	230	2	report	report	NOUN
aji-173	230	3	of	of	ADP
aji-173	230	4	a	a	DET
aji-173	230	5	symptomatic	symptomatic	ADJ
aji-173	230	6	progressive	progressive	ADJ
aji-173	230	7	myeloma	myeloma	NOUN
aji-173	230	8	during	during	ADP
aji-173	230	9	pregnancy	pregnancy	NOUN
aji-173	230	10	and	and	CCONJ
aji-173	230	11	postpartum	postpartum	NOUN
aji-173	230	12	period	period	NOUN
aji-173	230	13	from	from	ADP
aji-173	230	14	asymptomatic	asymptomatic	ADJ
aji-173	230	15	state	state	NOUN
aji-173	230	16	.	.	PUNCT
aji-173	231	1	hematology	hematology	NOUN
aji-173	231	2	reports	report	NOUN
aji-173	231	3	,	,	PUNCT
aji-173	231	4	15(2	15(2	NUM
aji-173	231	5	)	)	PUNCT
aji-173	231	6	,	,	PUNCT
aji-173	231	7	305–311	305–311	NUM
aji-173	231	8	.	.	PUNCT
aji-173	232	1	faze	faze	PROPN
aji-173	232	2	,	,	PUNCT
aji-173	232	3	f.	f.	PROPN
aji-173	232	4	(	(	PUNCT
aji-173	232	5	2019	2019	NUM
aji-173	232	6	)	)	PUNCT
aji-173	232	7	.	.	PUNCT
aji-173	233	1	an	an	DET
aji-173	233	2	approach	approach	NOUN
aji-173	233	3	to	to	ADP
aji-173	233	4	the	the	DET
aji-173	233	5	diagnosis	diagnosis	NOUN
aji-173	233	6	and	and	CCONJ
aji-173	233	7	management	management	NOUN
aji-173	233	8	of	of	ADP
aji-173	233	9	multiple	multiple	ADJ
aji-173	233	10	myeloma	myeloma	NOUN
aji-173	233	11	.	.	PUNCT
aji-173	234	1	samj	samj	NOUN
aji-173	234	2	:	:	PUNCT
aji-173	234	3	south	south	ADJ
aji-173	234	4	african	african	ADJ
aji-173	234	5	medical	medical	ADJ
aji-173	234	6	journal	journal	NOUN
aji-173	234	7	,	,	PUNCT
aji-173	234	8	109(10	109(10	NUM
aji-173	234	9	)	)	PUNCT
aji-173	234	10	.	.	PUNCT
aji-173	235	1	gertz	gertz	PROPN
aji-173	235	2	,	,	PUNCT
aji-173	235	3	m.	m.	NOUN
aji-173	235	4	a.	a.	PROPN
aji-173	235	5	(	(	PUNCT
aji-173	235	6	2008	2008	NUM
aji-173	235	7	)	)	PUNCT
aji-173	235	8	.	.	PUNCT
aji-173	236	1	new	new	ADJ
aji-173	236	2	targets	target	NOUN
aji-173	236	3	and	and	CCONJ
aji-173	236	4	treatments	treatment	NOUN
aji-173	236	5	in	in	ADP
aji-173	236	6	multiple	multiple	ADJ
aji-173	236	7	myeloma	myeloma	NOUN
aji-173	236	8	:	:	PUNCT
aji-173	236	9	src	src	NOUN
aji-173	236	10	family	family	NOUN
aji-173	236	11	kinases	kinase	NOUN
aji-173	236	12	as	as	ADP
aji-173	236	13	central	central	ADJ
aji-173	236	14	regulators	regulator	NOUN
aji-173	236	15	of	of	ADP
aji-173	236	16	disease	disease	NOUN
aji-173	236	17	progression	progression	NOUN
aji-173	236	18	.	.	PUNCT
aji-173	237	1	leukemia	leukemia	NOUN
aji-173	237	2	&	&	CCONJ
aji-173	237	3	lymphoma	lymphoma	PROPN
aji-173	237	4	,	,	PUNCT
aji-173	237	5	49(12	49(12	NUM
aji-173	237	6	)	)	PUNCT
aji-173	237	7	,	,	PUNCT
aji-173	237	8	22402245	22402245	NUM
aji-173	237	9	.	.	PUNCT
aji-173	238	1	hila	hila	PROPN
aji-173	238	2	,	,	PUNCT
aji-173	238	3	m.	m.	NOUN
aji-173	238	4	et	et	PROPN
aji-173	238	5	al	al	PROPN
aji-173	238	6	.	.	PROPN
aji-173	238	7	(	(	PUNCT
aji-173	238	8	2022	2022	NUM
aji-173	238	9	)	)	PUNCT
aji-173	238	10	.	.	PUNCT
aji-173	239	1	diagnosis	diagnosis	NOUN
aji-173	239	2	and	and	CCONJ
aji-173	239	3	management	management	NOUN
aji-173	239	4	of	of	ADP
aji-173	239	5	multiple	multiple	ADJ
aji-173	239	6	myeloma	myeloma	NOUN
aji-173	239	7	during	during	ADP
aji-173	239	8	pregnancy	pregnancy	NOUN
aji-173	239	9	:	:	PUNCT
aji-173	239	10	case	case	NOUN
aji-173	239	11	report	report	NOUN
aji-173	239	12	,	,	PUNCT
aji-173	239	13	review	review	NOUN
aji-173	239	14	of	of	ADP
aji-173	239	15	literature	literature	NOUN
aji-173	239	16	and	and	CCONJ
aji-173	239	17	update	update	NOUN
aji-173	239	18	on	on	ADP
aji-173	239	19	current	current	ADJ
aji-173	239	20	treatments.ther	treatments.ther	NUM
aji-173	239	21	adv	adv	PROPN
aji-173	239	22	hematol	hematol	NOUN
aji-173	239	23	.	.	PUNCT
aji-173	240	1	jan	jan	PROPN
aji-173	240	2	21:13/20406207211066173	21:13/20406207211066173	PROPN
aji-173	240	3	.	.	PUNCT
aji-173	241	1	johns	johns	PROPN
aji-173	241	2	hopkins	hopkins	PROPN
aji-173	241	3	university	university	PROPN
aji-173	241	4	school	school	NOUN
aji-173	241	5	of	of	ADP
aji-173	241	6	medicine	medicine	NOUN
aji-173	241	7	,	,	PUNCT
aji-173	241	8	msd	msd	NOUN
aji-173	241	9	manuals	manual	NOUN
aji-173	241	10	professional	professional	ADJ
aji-173	241	11	.	.	PUNCT
aji-173	242	1	(	(	PUNCT
aji-173	242	2	2024	2024	NUM
aji-173	242	3	)	)	PUNCT
aji-173	242	4	.	.	PUNCT
aji-173	243	1	myélome	myélome	ADJ
aji-173	243	2	multiple	multiple	NOUN
aji-173	243	3	.	.	PUNCT
aji-173	244	1	kumar	kumar	PROPN
aji-173	244	2	,	,	PUNCT
aji-173	244	3	s.	s.	PROPN
aji-173	244	4	(	(	PUNCT
aji-173	244	5	2003	2003	NUM
aji-173	244	6	)	)	PUNCT
aji-173	244	7	response	response	NOUN
aji-173	244	8	rate	rate	NOUN
aji-173	244	9	,	,	PUNCT
aji-173	244	10	durability	durability	NOUN
aji-173	244	11	of	of	ADP
aji-173	244	12	response	response	NOUN
aji-173	244	13	and	and	CCONJ
aji-173	244	14	survivalafter	survivalafter	ADJ
aji-173	244	15	thalidomide	thalidomide	NOUN
aji-173	244	16	therapy	therapy	NOUN
aji-173	244	17	for	for	ADP
aji-173	244	18	relapsed	relapse	VERB
aji-173	244	19	multiple	multiple	ADJ
aji-173	244	20	myeloma	myeloma	NOUN
aji-173	244	21	.	.	PUNCT
aji-173	245	1	mayo	mayo	PROPN
aji-173	245	2	clinic	clinic	NOUN
aji-173	245	3	proceedings	proceeding	NOUN
aji-173	245	4	78(1)34	78(1)34	NUM
aji-173	245	5	-	-	SYM
aji-173	245	6	39	39	NUM
aji-173	245	7	.	.	PUNCT
aji-173	246	1	kyle	kyle	PROPN
aji-173	246	2	,	,	PUNCT
aji-173	246	3	r.	r.	PROPN
aji-173	246	4	a.	a.	PROPN
aji-173	246	5	,	,	PUNCT
aji-173	246	6	&	&	CCONJ
aji-173	246	7	rajkumar	rajkumar	PROPN
aji-173	246	8	,	,	PUNCT
aji-173	246	9	s.	s.	PROPN
aji-173	246	10	v.	v.	PROPN
aji-173	246	11	(	(	PUNCT
aji-173	246	12	2004	2004	NUM
aji-173	246	13	)	)	PUNCT
aji-173	246	14	.	.	PUNCT
aji-173	247	1	multiple	multiple	ADJ
aji-173	247	2	myeloma	myeloma	PROPN
aji-173	247	3	.	.	PUNCT
aji-173	248	1	new	new	PROPN
aji-173	248	2	england	england	PROPN
aji-173	248	3	journal	journal	PROPN
aji-173	248	4	of	of	ADP
aji-173	248	5	medicine	medicine	NOUN
aji-173	248	6	,	,	PUNCT
aji-173	248	7	350(3	350(3	NUM
aji-173	248	8	)	)	PUNCT
aji-173	248	9	,	,	PUNCT
aji-173	248	10	282–292	282–292	NUM
aji-173	248	11	.	.	PUNCT
aji-173	249	1	la	la	PROPN
aji-173	249	2	revue	revue	PROPN
aji-173	249	3	du	du	PROPN
aji-173	249	4	praticien	praticien	PROPN
aji-173	249	5	.	.	PUNCT
aji-173	250	1	(	(	PUNCT
aji-173	250	2	2023	2023	NUM
aji-173	250	3	)	)	PUNCT
aji-173	250	4	.	.	PUNCT
aji-173	251	1	myélome	myélome	ADJ
aji-173	251	2	multiple	multiple	NOUN
aji-173	251	3	:	:	PUNCT
aji-173	251	4	aspects	aspect	NOUN
aji-173	251	5	cliniques	clinique	NOUN
aji-173	251	6	et	et	NOUN
aji-173	251	7	thérapeutiques	thérapeutique	NOUN
aji-173	251	8	.	.	PUNCT
aji-173	252	1	lee	lee	PROPN
aji-173	252	2	,	,	PUNCT
aji-173	252	3	g.	g.	PROPN
aji-173	252	4	w.	w.	PROPN
aji-173	252	5	,	,	PUNCT
aji-173	252	6	park	park	PROPN
aji-173	252	7	,	,	PUNCT
aji-173	252	8	s.	s.	PROPN
aji-173	252	9	w.	w.	PROPN
aji-173	252	10	,	,	PUNCT
aji-173	252	11	go	go	VERB
aji-173	252	12	,	,	PUNCT
aji-173	252	13	s.	s.	PROPN
aji-173	252	14	i.	i.	PROPN
aji-173	252	15	,	,	PUNCT
aji-173	252	16	kim	kim	PROPN
aji-173	252	17	,	,	PUNCT
aji-173	252	18	h.	h.	PROPN
aji-173	252	19	g.	g.	PROPN
aji-173	252	20	,	,	PUNCT
aji-173	252	21	kim	kim	PROPN
aji-173	252	22	,	,	PUNCT
aji-173	252	23	m.	m.	PROPN
aji-173	252	24	k.	k.	PROPN
aji-173	252	25	,	,	PUNCT
aji-173	252	26	min	min	PROPN
aji-173	252	27	,	,	PUNCT
aji-173	252	28	c.	c.	PROPN
aji-173	252	29	k.	k.	PROPN
aji-173	252	30	,	,	PUNCT
aji-173	252	31	...	...	PUNCT
aji-173	252	32	&	&	CCONJ
aji-173	252	33	kim	kim	PROPN
aji-173	252	34	,	,	PUNCT
aji-173	252	35	k.	k.	PROPN
aji-173	252	36	(	(	PUNCT
aji-173	252	37	2018	2018	NUM
aji-173	252	38	)	)	PUNCT
aji-173	252	39	.	.	PUNCT
aji-173	253	1	the	the	DET
aji-173	253	2	derived	derive	VERB
aji-173	253	3	neutrophil	neutrophil	NOUN
aji-173	253	4	-	-	PUNCT
aji-173	253	5	to	to	ADP
aji-173	253	6	-	-	PUNCT
aji-173	253	7	lymphocyte	lymphocyte	ADJ
aji-173	253	8	ratio	ratio	NOUN
aji-173	253	9	is	be	AUX
aji-173	253	10	an	an	DET
aji-173	253	11	independent	independent	ADJ
aji-173	253	12	prognostic	prognostic	ADJ
aji-173	253	13	factor	factor	NOUN
aji-173	253	14	in	in	ADP
aji-173	253	15	transplantation	transplantation	NOUN
aji-173	253	16	ineligible	ineligible	ADJ
aji-173	253	17	patients	patient	NOUN
aji-173	253	18	with	with	ADP
aji-173	253	19	multiple	multiple	ADJ
aji-173	253	20	myeloma	myeloma	NOUN
aji-173	253	21	.	.	PUNCT
aji-173	254	1	acta	acta	PROPN
aji-173	254	2	haematologica	haematologica	PROPN
aji-173	254	3	,	,	PUNCT
aji-173	254	4	140(3	140(3	NUM
aji-173	254	5	)	)	PUNCT
aji-173	254	6	,	,	PUNCT
aji-173	254	7	146	146	NUM
aji-173	254	8	-	-	SYM
aji-173	254	9	156	156	NUM
aji-173	254	10	.	.	PUNCT
aji-173	255	1	mor	mor	PROPN
aji-173	255	2	,	,	PUNCT
aji-173	255	3	g.	g.	PROPN
aji-173	255	4	,	,	PUNCT
aji-173	255	5	&	&	CCONJ
aji-173	255	6	cardenas	cardenas	PROPN
aji-173	255	7	,	,	PUNCT
aji-173	255	8	i.	i.	PROPN
aji-173	255	9	(	(	PUNCT
aji-173	255	10	2010	2010	NUM
aji-173	255	11	)	)	PUNCT
aji-173	255	12	.	.	PUNCT
aji-173	256	1	the	the	DET
aji-173	256	2	immune	immune	ADJ
aji-173	256	3	system	system	NOUN
aji-173	256	4	in	in	ADP
aji-173	256	5	pregnancy	pregnancy	NOUN
aji-173	256	6	:	:	PUNCT
aji-173	256	7	a	a	DET
aji-173	256	8	unique	unique	ADJ
aji-173	256	9	complexity	complexity	NOUN
aji-173	256	10	.	.	PUNCT
aji-173	257	1	american	american	ADJ
aji-173	257	2	journal	journal	PROPN
aji-173	257	3	of	of	ADP
aji-173	257	4	reproductive	reproductive	ADJ
aji-173	257	5	immunology	immunology	NOUN
aji-173	257	6	,	,	PUNCT
aji-173	257	7	63(6	63(6	PROPN
aji-173	257	8	)	)	PUNCT
aji-173	257	9	,	,	PUNCT
aji-173	257	10	425–433	425–433	NUM
aji-173	257	11	.	.	PUNCT
aji-173	258	1	pajor	pajor	PROPN
aji-173	258	2	,	,	PUNCT
aji-173	258	3	a.	a.	NOUN
aji-173	258	4	(	(	PUNCT
aji-173	258	5	1991	1991	NUM
aji-173	258	6	)	)	PUNCT
aji-173	258	7	.	.	PUNCT
aji-173	259	1	multiple	multiple	ADJ
aji-173	259	2	myeloma	myeloma	NOUN
aji-173	259	3	in	in	ADP
aji-173	259	4	pregnancy	pregnancy	NOUN
aji-173	259	5	.	.	PUNCT
aji-173	260	1	international	international	ADJ
aji-173	260	2	journal	journal	PROPN
aji-173	260	3	of	of	ADP
aji-173	260	4	gynaecology	gynaecology	NOUN
aji-173	260	5	and	and	CCONJ
aji-173	260	6	obstetrics	obstetric	NOUN
aji-173	260	7	,	,	PUNCT
aji-173	260	8	35(4	35(4	NUM
aji-173	260	9	)	)	PUNCT
aji-173	260	10	,	,	PUNCT
aji-173	260	11	341–342	341–342	NUM
aji-173	260	12	.	.	PUNCT
aji-173	260	13	https://doi.org/10.1016/00207292(91)90669-v	https://doi.org/10.1016/00207292(91)90669-v	PROPN
aji-173	260	14	palumbo	palumbo	PROPN
aji-173	260	15	,	,	PUNCT
aji-173	260	16	a.	a.	PROPN
aji-173	260	17	,	,	PUNCT
aji-173	260	18	&	&	CCONJ
aji-173	260	19	anderson	anderson	PROPN
aji-173	260	20	,	,	PUNCT
aji-173	260	21	k.	k.	PROPN
aji-173	260	22	(	(	PUNCT
aji-173	260	23	2011	2011	NUM
aji-173	260	24	)	)	PUNCT
aji-173	260	25	.	.	PUNCT
aji-173	261	1	multiple	multiple	ADJ
aji-173	261	2	myeloma	myeloma	PROPN
aji-173	261	3	.	.	PUNCT
aji-173	262	1	new	new	PROPN
aji-173	262	2	england	england	PROPN
aji-173	262	3	journal	journal	PROPN
aji-173	262	4	of	of	ADP
aji-173	262	5	medicine	medicine	NOUN
aji-173	262	6	,	,	PUNCT
aji-173	262	7	364(11	364(11	NUM
aji-173	262	8	)	)	PUNCT
aji-173	262	9	,	,	PUNCT
aji-173	262	10	1046–1060	1046–1060	NUM
aji-173	262	11	.	.	PUNCT
aji-173	263	1	palumbo	palumbo	PROPN
aji-173	263	2	,	,	PUNCT
aji-173	263	3	a.	a.	PROPN
aji-173	263	4	,	,	PUNCT
aji-173	263	5	et	et	PROPN
aji-173	263	6	al	al	PROPN
aji-173	263	7	.	.	PROPN
aji-173	263	8	(	(	PUNCT
aji-173	263	9	2020	2020	NUM
aji-173	263	10	)	)	PUNCT
aji-173	263	11	.	.	PUNCT
aji-173	264	1	treatment	treatment	NOUN
aji-173	264	2	of	of	ADP
aji-173	264	3	newly	newly	ADV
aji-173	264	4	diagnosed	diagnose	VERB
aji-173	264	5	multiple	multiple	ADJ
aji-173	264	6	myeloma	myeloma	NOUN
aji-173	264	7	:	:	PUNCT
aji-173	264	8	updated	update	VERB
aji-173	264	9	recommendations	recommendation	NOUN
aji-173	264	10	.	.	PUNCT
aji-173	265	1	journal	journal	NOUN
aji-173	265	2	of	of	ADP
aji-173	265	3	clinical	clinical	ADJ
aji-173	265	4	oncology	oncology	NOUN
aji-173	265	5	,	,	PUNCT
aji-173	265	6	38(15	38(15	NUM
aji-173	265	7	)	)	PUNCT
aji-173	265	8	,	,	PUNCT
aji-173	265	9	1702–1714	1702–1714	NUM
aji-173	265	10	.	.	PUNCT
aji-173	266	1	rajkumar	rajkumar	PROPN
aji-173	266	2	,	,	PUNCT
aji-173	266	3	s.	s.	PROPN
aji-173	266	4	v.	v.	PROPN
aji-173	266	5	(	(	PUNCT
aji-173	266	6	1999	1999	NUM
aji-173	266	7	)	)	PUNCT
aji-173	266	8	.	.	PUNCT
aji-173	267	1	prognostic	prognostic	ADJ
aji-173	267	2	factors	factor	NOUN
aji-173	267	3	in	in	ADP
aji-173	267	4	multiple	multiple	ADJ
aji-173	267	5	myeloma	myeloma	NOUN
aji-173	267	6	.	.	PUNCT
aji-173	268	1	hematology	hematology	NOUN
aji-173	268	2	/	/	SYM
aji-173	268	3	oncology	oncology	NOUN
aji-173	268	4	clinics	clinic	NOUN
aji-173	268	5	of	of	ADP
aji-173	268	6	north	north	PROPN
aji-173	268	7	america	america	PROPN
aji-173	268	8	,	,	PUNCT
aji-173	268	9	13(6	13(6	PROPN
aji-173	268	10	)	)	PUNCT
aji-173	268	11	,	,	PUNCT
aji-173	268	12	1295–131	1295–131	PROPN
aji-173	268	13	.	.	PUNCT
aji-173	269	1	rajkumar	rajkumar	PROPN
aji-173	269	2	,	,	PUNCT
aji-173	269	3	s.v	s.v	PROPN
aji-173	269	4	.	.	PROPN
aji-173	269	5	(	(	PUNCT
aji-173	269	6	2011	2011	NUM
aji-173	269	7	)	)	PUNCT
aji-173	269	8	.	.	PUNCT
aji-173	270	1	multiple	multiple	ADJ
aji-173	270	2	myeloma	myeloma	NOUN
aji-173	270	3	:	:	PUNCT
aji-173	270	4	2011update	2011update	NUM
aji-173	270	5	on	on	ADP
aji-173	270	6	diagnosis	diagnosis	NOUN
aji-173	270	7	,	,	PUNCT
aji-173	270	8	risk	risk	NOUN
aji-173	270	9	stratificationand	stratificationand	NOUN
aji-173	270	10	management	management	PROPN
aji-173	270	11	am	be	AUX
aji-173	270	12	j	j	PROPN
aji-173	270	13	hematol	hematol	NOUN
aji-173	270	14	.	.	PUNCT
aji-173	271	1	jan;86(1):57	jan;86(1):57	PROPN
aji-173	271	2	-	-	PUNCT
aji-173	271	3	65	65	PROPN
aji-173	271	4	.	.	PUNCT
aji-173	272	1	rajkumar	rajkumar	PROPN
aji-173	272	2	,	,	PUNCT
aji-173	272	3	s.	s.	PROPN
aji-173	272	4	v.	v.	PROPN
aji-173	272	5	(	(	PUNCT
aji-173	272	6	2020	2020	NUM
aji-173	272	7	)	)	PUNCT
aji-173	272	8	.	.	PUNCT
aji-173	273	1	multiple	multiple	ADJ
aji-173	273	2	myeloma	myeloma	NOUN
aji-173	273	3	:	:	PUNCT
aji-173	273	4	2020	2020	NUM
aji-173	273	5	update	update	NOUN
aji-173	273	6	on	on	ADP
aji-173	273	7	diagnosis	diagnosis	NOUN
aji-173	273	8	,	,	PUNCT
aji-173	273	9	risk	risk	NOUN
aji-173	273	10	-	-	PUNCT
aji-173	273	11	stratification	stratification	NOUN
aji-173	273	12	and	and	CCONJ
aji-173	273	13	management	management	NOUN
aji-173	273	14	.	.	PUNCT
aji-173	274	1	american	american	PROPN
aji-173	274	2	journal	journal	PROPN
aji-173	274	3	of	of	ADP
aji-173	274	4	meriche	meriche	PROPN
aji-173	274	5	et	et	PROPN
aji-173	274	6	al	al	PROPN
aji-173	274	7	.	.	PROPN
aji-173	274	8	;	;	PUNCT
aji-173	274	9	asian	asian	PROPN
aji-173	274	10	j.	j.	PROPN
aji-173	274	11	immunol	immunol	PROPN
aji-173	274	12	.	.	PROPN
aji-173	274	13	,	,	PUNCT
aji-173	274	14	vol	vol	NOUN
aji-173	274	15	.	.	PROPN
aji-173	274	16	8	8	NUM
aji-173	274	17	,	,	PUNCT
aji-173	274	18	no	no	INTJ
aji-173	274	19	.	.	NOUN
aji-173	274	20	1	1	NUM
aji-173	274	21	,	,	PUNCT
aji-173	274	22	pp	pp	ADJ
aji-173	274	23	.	.	PUNCT
aji-173	275	1	222	222	NUM
aji-173	275	2	-	-	SYM
aji-173	275	3	229	229	NUM
aji-173	275	4	,	,	PUNCT
aji-173	275	5	2025	2025	NUM
aji-173	275	6	;	;	PUNCT
aji-173	275	7	article	article	NOUN
aji-173	275	8	no.aji.141940	no.aji.141940	NOUN
aji-173	275	9	229	229	NUM
aji-173	275	10	hematology	hematology	NOUN
aji-173	275	11	,	,	PUNCT
aji-173	275	12	95(5	95(5	NUM
aji-173	275	13	)	)	PUNCT
aji-173	275	14	,	,	PUNCT
aji-173	275	15	548–567	548–567	NUM
aji-173	275	16	.	.	PUNCT
aji-173	276	1	https://doi.org/10.1002/ajh.25791	https://doi.org/10.1002/ajh.25791	NOUN
aji-173	276	2	smith	smith	PROPN
aji-173	276	3	m.	m.	PROPN
aji-173	276	4	et	et	PROPN
aji-173	276	5	al	al	PROPN
aji-173	276	6	.	.	PROPN
aji-173	276	7	(	(	PUNCT
aji-173	276	8	2021	2021	NUM
aji-173	276	9	)	)	PUNCT
aji-173	276	10	.	.	PUNCT
aji-173	277	1	early	early	ADJ
aji-173	277	2	detection	detection	NOUN
aji-173	277	3	of	of	ADP
aji-173	277	4	myeloma.innovait	myeloma.innovait	NUM
aji-173	277	5	volume	volume	NOUN
aji-173	277	6	14	14	NUM
aji-173	277	7	issue	issue	NOUN
aji-173	277	8	7	7	NUM
aji-173	277	9	.	.	PUNCT
aji-173	278	1	steinbach	steinbach	PROPN
aji-173	278	2	,	,	PUNCT
aji-173	278	3	m.	m.	NOUN
aji-173	278	4	(	(	PUNCT
aji-173	278	5	2024	2024	NUM
aji-173	278	6	)	)	PUNCT
aji-173	278	7	.	.	PUNCT
aji-173	279	1	multiple	multiple	ADJ
aji-173	279	2	myeloma	myeloma	NOUN
aji-173	279	3	in	in	ADP
aji-173	279	4	young	young	ADJ
aji-173	279	5	patients	patient	NOUN
aji-173	279	6	:	:	PUNCT
aji-173	279	7	a	a	DET
aji-173	279	8	scoping	scope	VERB
aji-173	279	9	review	review	NOUN
aji-173	279	10	.	.	PUNCT
aji-173	280	1	clinical	clinical	ADJ
aji-173	280	2	lymphoma	lymphoma	NOUN
aji-173	280	3	,	,	PUNCT
aji-173	280	4	myeloma	myeloma	NOUN
aji-173	280	5	&	&	CCONJ
aji-173	280	6	leukemia	leukemia	PROPN
aji-173	280	7	,	,	PUNCT
aji-173	280	8	24(1	24(1	NUM
aji-173	280	9	)	)	PUNCT
aji-173	280	10	,	,	PUNCT
aji-173	280	11	15–22	15–22	NUM
aji-173	280	12	.	.	PUNCT
aji-173	281	1	https://doi.org/10.1016/j.clml.2023.08.019	https://doi.org/10.1016/j.clml.2023.08.019	PROPN
aji-173	281	2	szydełko	szydełko	NOUN
aji-173	281	3	,	,	PUNCT
aji-173	281	4	m.	m.	NOUN
aji-173	281	5	(	(	PUNCT
aji-173	281	6	2019	2019	NUM
aji-173	281	7	)	)	PUNCT
aji-173	281	8	.	.	PUNCT
aji-173	282	1	multiple	multiple	ADJ
aji-173	282	2	myeloma	myeloma	NOUN
aji-173	282	3	during	during	ADP
aji-173	282	4	pregnancy	pregnancy	NOUN
aji-173	282	5	as	as	ADP
aji-173	282	6	a	a	DET
aji-173	282	7	challenge	challenge	NOUN
aji-173	282	8	in	in	ADP
aji-173	282	9	clinical	clinical	ADJ
aji-173	282	10	practice	practice	NOUN
aji-173	282	11	–	–	PUNCT
aji-173	282	12	a	a	DET
aji-173	282	13	review	review	NOUN
aji-173	282	14	.	.	PUNCT
aji-173	283	1	journal	journal	PROPN
aji-173	283	2	of	of	ADP
aji-173	283	3	education	education	NOUN
aji-173	283	4	,	,	PUNCT
aji-173	283	5	health	health	NOUN
aji-173	283	6	and	and	CCONJ
aji-173	283	7	sport	sport	NOUN
aji-173	283	8	,	,	PUNCT
aji-173	283	9	9(8	9(8	NUM
aji-173	283	10	)	)	PUNCT
aji-173	283	11	,	,	PUNCT
aji-173	283	12	920	920	NUM
aji-173	283	13	–	–	PUNCT
aji-173	283	14	937	937	NUM
aji-173	283	15	.	.	PUNCT
aji-173	284	1	terpos	terpos	PROPN
aji-173	284	2	,	,	PUNCT
aji-173	284	3	e.	e.	PROPN
aji-173	284	4	,	,	PUNCT
aji-173	284	5	&	&	CCONJ
aji-173	284	6	dimopoulos	dimopoulos	PROPN
aji-173	284	7	,	,	PUNCT
aji-173	284	8	m.	m.	NOUN
aji-173	284	9	a.	a.	NOUN
aji-173	284	10	(	(	PUNCT
aji-173	284	11	2005	2005	NUM
aji-173	284	12	)	)	PUNCT
aji-173	284	13	.	.	PUNCT
aji-173	285	1	myeloma	myeloma	NOUN
aji-173	285	2	bone	bone	NOUN
aji-173	285	3	disease	disease	NOUN
aji-173	285	4	:	:	PUNCT
aji-173	285	5	pathophysiology	pathophysiology	NOUN
aji-173	285	6	and	and	CCONJ
aji-173	285	7	management	management	NOUN
aji-173	285	8	.	.	PUNCT
aji-173	286	1	annals	annal	NOUN
aji-173	286	2	of	of	ADP
aji-173	286	3	oncology	oncology	NOUN
aji-173	286	4	,	,	PUNCT
aji-173	286	5	16(2	16(2	NUM
aji-173	286	6	)	)	PUNCT
aji-173	286	7	,	,	PUNCT
aji-173	286	8	122–126	122–126	NUM
aji-173	286	9	.	.	PUNCT
aji-173	287	1	terpos	terpos	PROPN
aji-173	287	2	,	,	PUNCT
aji-173	287	3	e.	e.	PROPN
aji-173	287	4	,	,	PUNCT
aji-173	287	5	engelhardt	engelhardt	PROPN
aji-173	287	6	,	,	PUNCT
aji-173	287	7	m.	m.	NOUN
aji-173	287	8	,	,	PUNCT
aji-173	287	9	cook	cook	NOUN
aji-173	287	10	,	,	PUNCT
aji-173	287	11	g.	g.	PROPN
aji-173	287	12	,	,	PUNCT
aji-173	287	13	gay	gay	PROPN
aji-173	287	14	,	,	PUNCT
aji-173	287	15	f.	f.	PROPN
aji-173	287	16	,	,	PUNCT
aji-173	287	17	mateos	mateo	NOUN
aji-173	287	18	,	,	PUNCT
aji-173	287	19	m.	m.	NOUN
aji-173	287	20	v.	v.	NOUN
aji-173	287	21	,	,	PUNCT
aji-173	287	22	ntanasis	ntanasis	NOUN
aji-173	287	23	-	-	PUNCT
aji-173	287	24	stathopoulos	stathopoulo	NOUN
aji-173	287	25	,	,	PUNCT
aji-173	287	26	i.	i.	PROPN
aji-173	287	27	,	,	PUNCT
aji-173	287	28	...	...	PUNCT
aji-173	287	29	&	&	CCONJ
aji-173	287	30	sonneveld	sonneveld	PROPN
aji-173	287	31	,	,	PUNCT
aji-173	287	32	p.	p.	NOUN
aji-173	287	33	(	(	PUNCT
aji-173	287	34	2020	2020	NUM
aji-173	287	35	)	)	PUNCT
aji-173	287	36	.	.	PUNCT
aji-173	288	1	management	management	NOUN
aji-173	288	2	of	of	ADP
aji-173	288	3	patients	patient	NOUN
aji-173	288	4	with	with	ADP
aji-173	288	5	multiple	multiple	ADJ
aji-173	288	6	myeloma	myeloma	NOUN
aji-173	288	7	in	in	ADP
aji-173	288	8	the	the	DET
aji-173	288	9	era	era	NOUN
aji-173	288	10	of	of	ADP
aji-173	288	11	covid-19	covid-19	PROPN
aji-173	288	12	pandemic	pandemic	NOUN
aji-173	288	13	:	:	PUNCT
aji-173	288	14	a	a	DET
aji-173	288	15	consensus	consensus	NOUN
aji-173	288	16	paper	paper	NOUN
aji-173	288	17	from	from	ADP
aji-173	288	18	the	the	DET
aji-173	288	19	european	european	PROPN
aji-173	288	20	myeloma	myeloma	PROPN
aji-173	288	21	network	network	PROPN
aji-173	288	22	(	(	PUNCT
aji-173	288	23	emn	emn	PROPN
aji-173	288	24	)	)	PUNCT
aji-173	288	25	.	.	PUNCT
aji-173	289	1	leukemia	leukemia	NOUN
aji-173	289	2	,	,	PUNCT
aji-173	289	3	34(8	34(8	NUM
aji-173	289	4	)	)	PUNCT
aji-173	289	5	,	,	PUNCT
aji-173	289	6	20002011	20002011	NUM
aji-173	289	7	.	.	PUNCT
aji-173	290	1	terpos	terpos	PROPN
aji-173	290	2	,	,	PUNCT
aji-173	290	3	e.	e.	PROPN
aji-173	290	4	,	,	PUNCT
aji-173	290	5	&	&	CCONJ
aji-173	290	6	ntanasis	ntanasis	NOUN
aji-173	290	7	-	-	PUNCT
aji-173	290	8	stathopoulos	stathopoulos	ADV
aji-173	290	9	,	,	PUNCT
aji-173	290	10	i.	i.	PROPN
aji-173	290	11	(	(	PUNCT
aji-173	290	12	2020	2020	NUM
aji-173	290	13	)	)	PUNCT
aji-173	290	14	.	.	PUNCT
aji-173	291	1	clinical	clinical	ADJ
aji-173	291	2	updates	update	NOUN
aji-173	291	3	regarding	regard	VERB
aji-173	291	4	multiple	multiple	ADJ
aji-173	291	5	myeloma	myeloma	NOUN
aji-173	291	6	from	from	ADP
aji-173	291	7	the	the	DET
aji-173	291	8	2019	2019	NUM
aji-173	291	9	american	american	ADJ
aji-173	291	10	society	society	NOUN
aji-173	291	11	of	of	ADP
aji-173	291	12	hematology	hematology	NOUN
aji-173	291	13	annual	annual	ADJ
aji-173	291	14	meeting	meeting	NOUN
aji-173	291	15	.	.	PUNCT
aji-173	292	1	clinical	clinical	ADJ
aji-173	292	2	lymphoma	lymphoma	NOUN
aji-173	292	3	myeloma	myeloma	NOUN
aji-173	292	4	and	and	CCONJ
aji-173	292	5	leukemia	leukemia	NOUN
aji-173	292	6	,	,	PUNCT
aji-173	292	7	20(8	20(8	NOUN
aji-173	292	8	)	)	PUNCT
aji-173	292	9	,	,	PUNCT
aji-173	292	10	499	499	NUM
aji-173	292	11	-	-	SYM
aji-173	292	12	508	508	NUM
aji-173	292	13	.	.	PUNCT
aji-173	293	1	disclaimer	disclaimer	ADJ
aji-173	293	2	/	/	SYM
aji-173	293	3	publisher	publisher	NOUN
aji-173	293	4	’s	’s	PART
aji-173	293	5	note	note	NOUN
aji-173	293	6	:	:	PUNCT
aji-173	293	7	the	the	DET
aji-173	293	8	statements	statement	NOUN
aji-173	293	9	,	,	PUNCT
aji-173	293	10	opinions	opinion	NOUN
aji-173	293	11	and	and	CCONJ
aji-173	293	12	data	datum	NOUN
aji-173	293	13	contained	contain	VERB
aji-173	293	14	in	in	ADP
aji-173	293	15	all	all	DET
aji-173	293	16	publications	publication	NOUN
aji-173	293	17	are	be	AUX
aji-173	293	18	solely	solely	ADV
aji-173	293	19	those	those	PRON
aji-173	293	20	of	of	ADP
aji-173	293	21	the	the	DET
aji-173	293	22	individual	individual	ADJ
aji-173	293	23	author(s	author(s	PROPN
aji-173	293	24	)	)	PUNCT
aji-173	293	25	and	and	CCONJ
aji-173	293	26	contributor(s	contributor(s	NOUN
aji-173	293	27	)	)	PUNCT
aji-173	293	28	and	and	CCONJ
aji-173	293	29	not	not	PART
aji-173	293	30	of	of	ADP
aji-173	293	31	the	the	DET
aji-173	293	32	publisher	publisher	NOUN
aji-173	293	33	and/or	and/or	CCONJ
aji-173	293	34	the	the	DET
aji-173	293	35	editor(s	editor(s	NOUN
aji-173	293	36	)	)	PUNCT
aji-173	293	37	.	.	PUNCT
aji-173	294	1	this	this	DET
aji-173	294	2	publisher	publisher	NOUN
aji-173	294	3	and/or	and/or	CCONJ
aji-173	294	4	the	the	DET
aji-173	294	5	editor(s	editor(s	NOUN
aji-173	294	6	)	)	PUNCT
aji-173	294	7	disclaim	disclaim	VERB
aji-173	294	8	responsibility	responsibility	NOUN
aji-173	294	9	for	for	ADP
aji-173	294	10	any	any	DET
aji-173	294	11	injury	injury	NOUN
aji-173	294	12	to	to	ADP
aji-173	294	13	people	people	NOUN
aji-173	294	14	or	or	CCONJ
aji-173	294	15	property	property	NOUN
aji-173	294	16	resulting	result	VERB
aji-173	294	17	from	from	ADP
aji-173	294	18	any	any	DET
aji-173	294	19	ideas	idea	NOUN
aji-173	294	20	,	,	PUNCT
aji-173	294	21	methods	method	NOUN
aji-173	294	22	,	,	PUNCT
aji-173	294	23	instructions	instruction	NOUN
aji-173	294	24	or	or	CCONJ
aji-173	294	25	products	product	NOUN
aji-173	294	26	referred	refer	VERB
aji-173	294	27	to	to	ADP
aji-173	294	28	in	in	ADP
aji-173	294	29	the	the	DET
aji-173	294	30	content	content	NOUN
aji-173	294	31	.	.	PUNCT
aji-173	295	1	_	_	PUNCT
aji-173	296	1	_	_	PUNCT
aji-173	297	1	_	_	PUNCT
aji-173	298	1	_	_	PUNCT
aji-173	299	1	_	_	PUNCT
aji-173	300	1	_	_	PUNCT
aji-173	301	1	_	_	PUNCT
aji-173	302	1	_	_	PUNCT
aji-173	303	1	_	_	PUNCT
aji-173	304	1	_	_	PUNCT
aji-173	305	1	_	_	PUNCT
aji-173	306	1	_	_	PUNCT
aji-173	307	1	_	_	PUNCT
aji-173	308	1	_	_	PUNCT
aji-173	309	1	_	_	PUNCT
aji-173	310	1	_	_	PUNCT
aji-173	311	1	_	_	PUNCT
aji-173	312	1	_	_	PUNCT
aji-173	313	1	_	_	PUNCT
aji-173	314	1	_	_	PUNCT
aji-173	315	1	_	_	PUNCT
aji-173	316	1	_	_	PUNCT
aji-173	317	1	_	_	PUNCT
aji-173	318	1	_	_	PUNCT
aji-173	319	1	_	_	PUNCT
aji-173	320	1	_	_	PUNCT
aji-173	321	1	_	_	PUNCT
aji-173	322	1	_	_	PUNCT
aji-173	323	1	_	_	PUNCT
aji-173	324	1	_	_	PUNCT
aji-173	325	1	_	_	PUNCT
aji-173	326	1	_	_	PUNCT
aji-173	327	1	_	_	PUNCT
aji-173	328	1	_	_	PUNCT
aji-173	329	1	_	_	PUNCT
aji-173	330	1	_	_	PUNCT
aji-173	331	1	_	_	PUNCT
aji-173	332	1	_	_	PUNCT
aji-173	333	1	_	_	PUNCT
aji-173	334	1	_	_	PUNCT
aji-173	335	1	_	_	PUNCT
aji-173	336	1	_	_	PUNCT
aji-173	337	1	_	_	PUNCT
aji-173	338	1	_	_	PUNCT
aji-173	339	1	_	_	PUNCT
aji-173	340	1	_	_	PUNCT
aji-173	341	1	_	_	PUNCT
aji-173	342	1	_	_	PUNCT
aji-173	343	1	_	_	PUNCT
aji-173	344	1	_	_	PUNCT
aji-173	345	1	_	_	PUNCT
aji-173	346	1	_	_	PUNCT
aji-173	347	1	_	_	PUNCT
aji-173	348	1	_	_	PUNCT
aji-173	349	1	_	_	PUNCT
aji-173	350	1	_	_	PUNCT
aji-173	351	1	_	_	PUNCT
aji-173	352	1	_	_	PUNCT
aji-173	353	1	_	_	PUNCT
aji-173	354	1	_	_	PUNCT
aji-173	355	1	_	_	PUNCT
aji-173	356	1	_	_	PUNCT
aji-173	357	1	_	_	PUNCT
aji-173	358	1	_	_	PUNCT
aji-173	359	1	_	_	PUNCT
aji-173	360	1	_	_	PUNCT
aji-173	361	1	_	_	PUNCT
aji-173	362	1	_	_	PUNCT
aji-173	363	1	_	_	PUNCT
aji-173	364	1	_	_	PUNCT
aji-173	365	1	_	_	PUNCT
aji-173	366	1	_	_	PUNCT
aji-173	367	1	_	_	PUNCT
aji-173	368	1	_	_	PUNCT
aji-173	369	1	_	_	PUNCT
aji-173	370	1	_	_	PUNCT
aji-173	371	1	_	_	PUNCT
aji-173	372	1	_	_	PUNCT
aji-173	373	1	_	_	PUNCT
aji-173	374	1	_	_	PUNCT
aji-173	375	1	_	_	PUNCT
aji-173	376	1	©	©	PRON
aji-173	376	2	copyright	copyright	NOUN
aji-173	376	3	(	(	PUNCT
aji-173	376	4	2025	2025	NUM
aji-173	376	5	):	):	PUNCT
aji-173	376	6	author(s	author(s	NOUN
aji-173	376	7	)	)	PUNCT
aji-173	376	8	.	.	PUNCT
aji-173	377	1	the	the	DET
aji-173	377	2	licensee	licensee	NOUN
aji-173	377	3	is	be	AUX
aji-173	377	4	the	the	DET
aji-173	377	5	journal	journal	PROPN
aji-173	377	6	publisher	publisher	NOUN
aji-173	377	7	.	.	PUNCT
aji-173	378	1	this	this	PRON
aji-173	378	2	is	be	AUX
aji-173	378	3	an	an	DET
aji-173	378	4	open	open	ADJ
aji-173	378	5	access	access	NOUN
aji-173	378	6	article	article	NOUN
aji-173	378	7	distributed	distribute	VERB
aji-173	378	8	under	under	ADP
aji-173	378	9	the	the	DET
aji-173	378	10	terms	term	NOUN
aji-173	378	11	of	of	ADP
aji-173	378	12	the	the	DET
aji-173	378	13	creative	creative	ADJ
aji-173	378	14	commons	common	NOUN
aji-173	378	15	attribution	attribution	NOUN
aji-173	378	16	license	license	NOUN
aji-173	378	17	(	(	PUNCT
aji-173	378	18	http://creativecommons.org/licenses/by/4.0	http://creativecommons.org/licenses/by/4.0	NOUN
aji-173	378	19	)	)	PUNCT
aji-173	378	20	,	,	PUNCT
aji-173	378	21	which	which	PRON
aji-173	378	22	permits	permit	VERB
aji-173	378	23	unrestricted	unrestricted	ADJ
aji-173	378	24	use	use	NOUN
aji-173	378	25	,	,	PUNCT
aji-173	378	26	distribution	distribution	NOUN
aji-173	378	27	,	,	PUNCT
aji-173	378	28	and	and	CCONJ
aji-173	378	29	reproduction	reproduction	NOUN
aji-173	378	30	in	in	ADP
aji-173	378	31	any	any	DET
aji-173	378	32	medium	medium	NOUN
aji-173	378	33	,	,	PUNCT
aji-173	378	34	provided	provide	VERB
aji-173	378	35	the	the	DET
aji-173	378	36	original	original	ADJ
aji-173	378	37	work	work	NOUN
aji-173	378	38	is	be	AUX
aji-173	378	39	properly	properly	ADV
aji-173	378	40	cited	cite	VERB
aji-173	378	41	.	.	PUNCT
aji-173	379	1	peer	peer	NOUN
aji-173	379	2	-	-	PUNCT
aji-173	379	3	review	review	NOUN
aji-173	379	4	history	history	NOUN
aji-173	379	5	:	:	PUNCT
aji-173	379	6	the	the	DET
aji-173	379	7	peer	peer	NOUN
aji-173	379	8	review	review	NOUN
aji-173	379	9	history	history	NOUN
aji-173	379	10	for	for	ADP
aji-173	379	11	this	this	DET
aji-173	379	12	paper	paper	NOUN
aji-173	379	13	can	can	AUX
aji-173	379	14	be	be	AUX
aji-173	379	15	accessed	access	VERB
aji-173	379	16	here	here	ADV
aji-173	379	17	:	:	PUNCT
aji-173	379	18	https://pr.sdiarticle5.com/review-history/141940	https://pr.sdiarticle5.com/review-history/141940	ADJ
aji-173	379	19	https://pr.sdiarticle5.com/review-history/141940	https://pr.sdiarticle5.com/review-history/141940	NOUN